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I. INTRODUCTION
Atrial fibrillation (AF), the most common sustained cardiac
rhythm disturbance, is increasing in prevalence as the
population ages. Although it is often associated with heart
disease, AF occurs in many patients with no detectable
disease. Hemodynamic impairment and thromboembolic
events result in significant morbidity, mortality, and cost.
Accordingly, the American College of Cardiology (ACC),
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the American Heart Association (AHA), and the European
Society of Cardiology (ESC) created a committee of experts
to establish guidelines for management of this arrhythmia.
The committee was composed of 8 members representing
the ACC and AHA, 4 representing the ESC, 1 from the
North American Society of Pacing and Electrophysiology
(NASPE), and a representative of the Johns Hopkins
University Evidence-Based Practice Center representing the
Agency for Healthcare Research and Quality’s report on
Atrial Fibrillation in the Elderly. This document was
reviewed by 3 official reviewers nominated by the ACC, 3
nominated by the AHA, and 3 nominated by the ESC, as
well as by the ACC Clinical Electrophysiology Committee,
the AHA ECG and Arrhythmia Committee, NASPE, and
25 reviewers nominated by the writing committee. The
document was approved for publication by the governing
bodies of the ACC, AHA, and ESC and officially endorsed
by NASPE. These guidelines will be reviewed annually by
the task force and will be considered current unless the task
force revises or withdraws them from distribution.
The committee conducted a comprehensive review of the
literature from 1980 to June 2000 relevant to AF using the
following databases: PubMed/Medline, EMBASE, the Co-
chrane Library (including the Cochrane Database of Sys-
tematic Reviews and the Cochrane Controlled Trials Reg-
istry), and Best Evidence. Searches were limited to English
language sources and to human subjects.
II. DEFINITIONS
A. Atrial Fibrillation
AF is a supraventricular tachyarrhythmia characterized by
uncoordinated atrial activation with consequent deteriora-
tion of atrial mechanical function. On the electrocardiogram
(ECG), AF is described by the replacement of consistent
P waves by rapid oscillations or fibrillatory waves that vary in
size, shape, and timing, associated with an irregular, fre-
quently rapid ventricular response when atrioventricular
(AV) conduction is intact (1). The ventricular response to
AF depends on electrophysiological properties of the AV
node, the level of vagal and sympathetic tone, and the action
of drugs (2). Regular RR intervals are possible in the
presence of AV block or interference by ventricular or
junctional tachycardia. A rapid, irregular, sustained, wide-
QRS-complex tachycardia strongly suggests AF with con-
duction over an accessory pathway or AF with underlying
bundle-branch block. Extremely rapid rates (over 200 bpm)
suggest the presence of an accessory pathway.
B. Related Arrhythmias
AF can be isolated or associated with other arrhythmias,
often atrial flutter or atrial tachycardia. Atrial flutter can
arise during treatment with antiarrhythmic agents pre-
scribed to prevent recurrent AF. Atrial flutter is more
organized than AF, with a saw-tooth pattern of regular atrial
activation called flutter (f) waves on the ECG, particularly
visible in leads II, III, and aVF. Untreated, the atrial rate
typically ranges from 240 to 320 beats per minute (bpm), with
f waves inverted in ECG leads II, III, and aVF and upright in
lead V1. The wave of activation in the right atrium (RA) may
be reversed, resulting in f waves that are upright in leads II, III,
and aVF and inverted in lead V1. Two-to-one AV block is
common, producing a ventricular rate of 120 to 160 bpm.
Atrial flutter can degenerate into AF, AF can initiate atrial
flutter, or the ECG pattern can alternate between atrial flutter
and AF, reflecting changing atrial activation.
Other atrial tachycardias, as well as AV reentrant tachy-
cardias and AV nodal reentrant tachycardias, can also
trigger AF. In other atrial tachycardias, P waves are readily
identified and are separated by an isoelectric baseline in 1 or
more ECG leads. The morphology of the P waves can help
localize the origin of atrial tachycardias. A unique type of
atrial tachycardia originates in the pulmonary veins (3), is
typically more rapid than 250 bpm, and often degenerates
into AF. Intracardiac mapping can help differentiate the
various atrial arrhythmias.
III. CLASSIFICATION
AF has a heterogeneous clinical presentation, occurring in
the presence or absence of detectable heart disease or related
symptoms. For example, the term “lone AF” has been
variously defined. The prognosis in terms of thromboem-
bolism and mortality is most benign when applied to young
individuals (aged less than 60 years) without clinical or
echocardiographic evidence of cardiopulmonary disease (4).
These patients have a favorable prognosis with respect to
thromboembolism and mortality. By virtue of aging or the
development of cardiac abnormalities, however, patients
move out of the lone AF category over time, and the risks of
thromboembolism and mortality rise. Lone AF is distin-
guished from idiopathic AF, which implies uncertainty
about its origin without reference to the age of the patient
or associated cardiovascular pathology. By convention, the
term nonvalvular AF is restricted to cases in which the
rhythm disturbance occurs in the absence of rheumatic
mitral stenosis or a prosthetic heart valve.
The classification scheme recommended in this docu-
ment represents a consensus driven by a desire for simplicity
and clinical relevance. The clinician should distinguish a
first-detected episode of AF, whether or not it is symptom-
atic or self-limited, recognizing that there can be uncer-
tainty about the duration of the episode and about previous
undetected episodes (Fig. 1). When a patient has had 2 or
more episodes, AF is considered recurrent. Once termi-
nated, recurrent AF is designated paroxysmal, and when
sustained, persistent. In the latter case, termination by
pharmacological therapy or electrical cardioversion does not
change the designation. Persistent AF can be either the first
presentation or a culmination of recurrent episodes of
paroxysmal AF. Persistent AF includes cases of long-
standing AF (eg, greater than 1 year), in which cardiover-
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sion has not been indicated or attempted, usually leading to
permanent AF (Fig. 1). The terminology defined in the
preceding paragraph applies to episodes of AF that last
more than 30 seconds and that are unrelated to a reversible
cause. AF secondary to a precipitating condition such as
acute myocardial infarction, cardiac surgery, myocarditis,
hyperthyroidism, or acute pulmonary disease is considered
separately. In these settings, treatment of the underlying
disorder concurrently with management of the episode of
AF usually eliminates the arrhythmia.
IV. EPIDEMIOLOGY AND PROGNOSIS
AF is the most common clinically significant cardiac ar-
rhythmia. In one series, AF accounted for 34.5% of patients
hospitalized with a cardiac rhythm disturbance (5). It has
been estimated that 2.2 million Americans have paroxysmal
or persistent AF (6).
A. Prevalence
The prevalence of AF is estimated at 0.4% of the general
population, increasing with age (7). AF is uncommon in
childhood except after cardiac surgery. It occurs in fewer
than 1% of those under 60 years of age but in more than 6%
of those over 80 years of age (8–10) (Fig. 2). The age-
adjusted prevalence is higher in men (10,11). Blacks have
less than half the age-adjusted risk of developing AF that is
seen in whites (12). The frequency of lone AF was less than
12% of all cases of AF in some series (4,10,13,14) but over
30% in others (15,16). The prevalence of AF increases with
the severity of congestive heart failure (HF) or valvular heart
disease.
B. Prognosis
The rate of ischemic stroke among patients with nonrheu-
matic AF averages 5% per year, which is 2 to 7 times the
rate for people without AF (8,9,15,17–19) (Fig. 3). One of
every 6 strokes occurs in patients with AF (20). Including
transient ischemic attacks and clinically silent strokes de-
tected radiographically, the rate of brain ischemia accom-
panying nonvalvular AF exceeds 7% per year (21–25). In the
Framingham Heart Study, patients with rheumatic heart
disease and AF had a 17-fold increased risk of stroke
compared with age-matched controls (26), and the attrib-
utable risk was 5 times greater than in those with nonrheu-
matic AF (9). Among AF patients from general practices in
France, the ALFA Study (Etude en Activite´ Liberale sur le
Fibrillation Auriculaire) found a 2.4% incidence of throm-
boembolism over a mean of 8.6 months of follow-up (15).
The annual risk of stroke attributable to AF increased from
1.5% in Framingham Study participants aged 50 to 59 years
to 23.5% for those aged 80 to 89 years (9). The total mortality
rate is approximately doubled in patients with AF compared
with patients in normal sinus rhythm and is linked with the
severity of underlying heart disease (8,11,18) (Fig. 3).
Figure 1. Patterns of atrial fibrillation. 1, episodes that generally last less than or equal to 7 days (most less than 24 h); 2, usually more than 7 days; 3,
cardioversion failed or not attempted; and 4, either paroxysmal or persistent AF may be recurrent.
Figure 2. Prevalence of AF in 2 American epidemiological studies.
Framingham indicates the Framingham Heart Study (9); CHS, Cardio-
vascular Health Study (10).
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V. PATHOPHYSIOLOGICAL MECHANISMS
A. Atrial Factors
1. Pathology of the Atrium in Patients With AF. The
atria of patients with persistent AF display structural ab-
normalities beyond those caused by underlying heart disease
(27). Patchy fibrosis with juxtaposition of normal and
diseased atrial fibers may account for nonhomogeneity of
atrial refractoriness (28,29). Fibrosis or fatty infiltration can
also affect the sinus node and might be a reaction to
inflammatory or degenerative processes that are difficult to
detect. The role of inflammation in the pathogenesis of AF
has not yet been evaluated, but histological changes consis-
tent with myocarditis were reported in 66% of biopsy speci-
mens from patients with lone AF (29). Infiltration of the atrial
myocardium can occur in amyloidosis, sarcoidosis, and hemo-
chromatosis. Atrial fiber hypertrophy has been described as a
major and sometimes the sole histological feature (28). Pro-
gressive atrial dilatation has been demonstrated echocardio-
graphically in patients with AF (30) and, like hypertrophy, can
be either a cause or a consequence of persistent AF.
2. Mechanisms of AF. Theories of the mechanism of AF
involve 2 main processes: enhanced automaticity in 1 or
several rapidly depolarizing foci and reentry involving 1 or
more circuits (31,32). Rapidly firing atrial foci, located in 1
or several of the superior pulmonary veins, can initiate AF in
susceptible patients (3,33). Foci also occur in the RA and
infrequently in the superior vena cava or coronary sinus
(3,33,34). The focal origin appears to be more important in
paroxysmal AF than in persistent AF. Ablation of such foci
can be curative (3).
The multiple-wavelet hypothesis as the mechanism of
reentrant AF was advanced by Moe and colleagues (31,35),
who proposed that fractionation of the wave fronts as they
propagate through the atria results in self-perpetuating
“daughter wavelets.” The number of wavelets present at any
time depends on the refractory period, mass, and conduc-
tion velocity in different parts of the atria.
Although the patterns of activation underlying the irreg-
ular atrial electrical activity of AF have traditionally been
described as disorganized or random, recent evidence has
emerged that AF is spatially organized. Based on mapping
studies of patients undergoing surgery for the Wolff-
Parkinson-White (WPW) syndrome, 3 patterns of induced
AF have been identified (36). Type I AF involves single
wave fronts propagating across the RA. Type II AF involves
1 or 2 wave fronts, and type III AF is characterized by
multiple activation wavelets propagating in different direc-
tions. Ultimately, a better understanding of electrophysio-
logical mechanisms will lead to the development of effective
preventive measures (37).
B. AV Conduction
1. General Aspects. The AV node is ordinarily the factor
that limits conduction during AF. The compact AV node is
located anteriorly in the triangle of Koch (38), surrounded
by transitional cells. There appear to be 2 distinct atrial
inputs to the AV node, posteriorly via the crista terminalis
and anteriorly via the interatrial septum. Studies on rabbit
AV nodal preparations show that during AF, propagation of
impulses through the AV node to the His bundle depends
in part on the relative timing of the anterior and posterior
septal activation inputs to the AV node (39). Other factors
that affect conduction through the AV node are its intrinsic
conduction and refractoriness, concealed conduction, and
autonomic tone.
2. AV Conduction in the WPW Syndrome. Accessory
pathways are muscle connections between the atrium and
ventricle that have the capacity to conduct rapidly. Conduc-
tion over an accessory pathway during AF can result in a
very rapid ventricular response that can be fatal (2,40).
Drugs such as digitalis, calcium channel antagonists, and
beta-blockers, which are usually given to slow conduction
across the AV node during AF, do not block conduction
over the accessory pathway and can even enhance conduc-
tion, resulting in hypotension or cardiac arrest (41). Patients
who develop AF with a rapid ventricular response associated
with hemodynamic instability that results from conduction
Figure 3. Relative risk of stroke and mortality in patients with AF compared with patients without AF. Source data are from the Framingham Heart Study
(11), Regional Heart Study (8), Whitehall study (8), and Manitoba study (18).
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over an accessory pathway should undergo immediate elec-
trical cardioversion. In the absence of hemodynamic insta-
bility or a preexcited ventricular response, intravenous pro-
cainamide and ibutilide are drugs of choice to achieve
pharmacological cardioversion or to block conduction over
the accessory pathway.
C. Myocardial and Hemodynamic Consequences of AF
During AF, 3 factors can affect hemodynamic function: loss
of synchronous atrial mechanical activity, irregularity of
ventricular response, and inappropriately rapid heart rate. A
marked decrease in cardiac output can occur with the loss of
atrial contraction, especially in patients with impaired dia-
stolic ventricular filling, hypertension, mitral stenosis, hy-
pertrophic cardiomyopathy (HCM), or restrictive cardio-
myopathies. The variation in RR intervals during AF can
also result in hemodynamic impairment. A persistently
rapid atrial rate can adversely affect atrial mechanical func-
tion (tachycardia-induced atrial cardiomyopathy) (2,42).
Such changes in atrial tissue might explain the delayed
recovery of atrial contractility in patients after cardioversion
to sinus rhythm.
A persistently elevated ventricular rate during AF (130
bpm or faster in one study) (43) can produce dilated
ventricular cardiomyopathy (2,43–46). It is critically impor-
tant to recognize tachycardia-induced cardiomyopathy, be-
cause control of the ventricular rate can lead to partial or
even complete reversal of the myopathic process. In fact, HF
can be the initial manifestation of AF. A variety of hypoth-
eses have been proposed to explain tachycardia-mediated
cardiomyopathy that involve myocardial energy depletion,
ischemia, abnormalities of calcium regulation, and remod-
eling, but the actual mechanisms responsible for this disor-
der are still unclear (47).
D. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism from the left atrium
(LA), the pathogenesis of thromboembolism is complex
(48). Up to 25% of AF-associated strokes can be due to
intrinsic cerebrovascular diseases, other cardiac sources of
embolism, or atheromatous pathology in the proximal aorta
(49,50). About half of elderly AF patients have chronic
hypertension (a major risk factor for cerebrovascular disease)
(19), and approximately 12% harbor cervical carotid artery
stenosis. Carotid atherosclerosis is not substantially more
prevalent in AF patients with stroke than in patients
without AF, however, and is probably a relatively minor
contributing factor (51).
1. Pathophysiology of Thrombus Formation. Thrombus
associated with AF arises most frequently in the LA
appendage (LAA). This cannot be examined reliably by
precordial (transthoracic) echocardiography (52), whereas
transesophageal Doppler echocardiography provides a sen-
sitive and specific method to assess LAA function (53) and
to detect thrombotic material. LAA flow velocities are
reduced because of loss of organized mechanical contraction
during AF (54,55). This substrate of decreased flow within
the LA/LAA has been associated with spontaneous echo
contrast, thrombus formation, and embolic events (56–62).
LAA flow velocities are lower in patients with atrial flutter
than what is usually seen with normal sinus rhythm but are
higher than with AF. Whether this accounts for the slightly
lower prevalence of LAA thrombus and perhaps a lower rate
of thromboembolism associated with atrial flutter is uncer-
tain.
In patients with AF, independent predictors of sponta-
neous echo contrast include LA size, LAA flow velocity
(56,63), left ventricular (LV) dysfunction, fibrinogen level
(62), hematocrit (61,62), and aortic atherosclerosis
(61,62,64,65). This phenomenon might be an echocardio-
graphic surrogate for regional coagulopathy and, when
dense, is of clinical value to identify AF patients at high risk
for thromboembolism (64), but its utility for prospective risk
stratification for thromboembolism beyond that achieved by
clinical assessment has not been established. Although
conventional clinical management is based on the presump-
tion that thrombus formation requires continuation of AF
for approximately 48 h, thrombi have been identified by
transesophageal echocardiography (TEE) within shorter
intervals (66,67).
Contrary to the prevalent view that systemic anticoagu-
lation for 4 weeks results in endocardial adherence and
organization of LAA thrombus, TEE studies have verified
resolution of thrombus in the majority of patients (68).
Similar observations have defined the transient nature of
LA/LAA dysfunction on conversion of AF, which provides
a mechanistic rationale for anticoagulation for several weeks
before and after successful cardioversion.
2. Clinical Implications. Because the pathophysiology of
thromboembolism in patients with AF is uncertain, the
mechanisms that link risk factors to ischemic stroke in AF
are also incompletely defined. The strong association be-
tween hypertension and stroke in AF is probably mediated
primarily by embolism that originates in the LAA (49), but
hypertension also increases the risk of noncardioembolic
strokes in AF (49,69). Hypertension in AF patients is
associated with reduced LAA flow velocity and spontaneous
echo contrast, which predisposes the patient to thrombus
formation (63,64,70). Ventricular diastolic dysfunction
might underlie the effect of hypertension on LA dynamics
(71,72). The effect of advancing age to increase stroke risk
in AF is multifactorial. In patients with AF, aging is
associated with LA enlargement, reduced LAA flow veloc-
ity, and spontaneous echo contrast, each of which predis-
poses to LA thrombus formation (30,63,64). Additionally,
age is a risk factor for atherosclerosis, including complex
aortic arch plaque, and is associated with stroke indepen-
dently of AF (65). LV systolic dysfunction predicts ischemic
stroke in AF patients receiving no antithrombotic therapy
(73–76).
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VI. ASSOCIATED CONDITIONS, CLINICAL
MANIFESTATIONS, AND QUALITY OF LIFE
A. Causes and Associated Conditions
1. Acute Causes of AF. AF can be related to acute,
temporary causes, including alcohol intake, surgery, electro-
cution, myocarditis, pulmonary embolism, other pulmonary
diseases, and hyperthyroidism. Successful treatment of the
underlying condition can eliminate AF. AF is a common
early postoperative complication of myocardial infarction
and of cardiac or thoracic surgery.
2. AF Without Associated Cardiovascular Disease. In
younger patients, approximately 30% to 45% of paroxysmal
cases and 20% to 25% of persistent cases of AF occur as lone
AF (13,15,16).
3. AF With Associated Cardiovascular Disease. Specific
cardiovascular conditions associated with AF include valvu-
lar heart disease (most often mitral), coronary artery disease
(CAD), and hypertension, particularly when LV hypertro-
phy (LVH) is present.
4. Neurogenic AF. The autonomic nervous system can
trigger AF in susceptible patients through heightened
vagal or adrenergic tone. Many patients experience onset
of AF during periods of enhanced parasympathetic or
sympathetic tone. Coumel (77) described a group of
patients that he characterized in terms of a vagal or
adrenergic form of AF. Patients with pure vagal or
adrenergic AF are uncommon, but if the history reveals a
pattern of onset of AF with features of one of these
syndromes, the clinician can select agents more likely to
prevent recurrent episodes.
B. Clinical Manifestations
AF can be symptomatic or asymptomatic, even in the same
patient. Symptoms vary with the ventricular rate, underlying
functional status, duration of AF, and individual patient
perceptions. The dysrhythmia can present for the first time
with an embolic complication or exacerbation of HF. Most
patients with AF complain of palpitations, chest pain,
dyspnea, fatigue, or lightheadedness. Release of atrial
natriuretic peptide can be associated with polyuria. AF
can lead to tachycardia-mediated cardiomyopathy, espe-
cially in patients who are unaware of the arrhythmia.
Syncope is an uncommon but serious complication that
usually indicates sinus node dysfunction, valvular aortic
stenosis, HCM, cerebrovascular disease, or an accessory
AV pathway.
C. Quality of Life
Although strokes certainly account for much of the func-
tional impairment associated with AF, the rhythm distur-
bance also decreases quality of life. In the Stroke Prevention
in Atrial Fibrillation (SPAF) study cohort, the New York
Heart Association functional classification, developed for HF,
was an insensitive index of quality of life in patients with AF
(78). In another study (79), 47 (68%) of 69 patients with
paroxysmal AF considered the dysrhythmia disruptive of their
lives. This perception was not associated with either the
frequency or duration of symptoms. The AFFIRM trial (Atrial
Fibrillation Follow-up Investigation of Rhythm Manage-
ment), which is still in progress, is comparing maintenance of
sinus rhythm with rate control in patients with AF, addressing
many facets of quality of life, as did the smaller PIAF
(Pharmacological Intervention in Atrial Fibrillation) study
(80). In selected patients, radiofrequency catheter ablation of
the AV node and pacemaker insertion improved quality-of-life
scores compared with medical therapy (81–86).
Long-term oral anticoagulant therapy, which involves
frequent blood testing and multiple drug interactions, is
another factor with important implications for the quality of
life of AF patients. Decision analysis found that only 61% of
97 patients preferred anticoagulation therapy to no treat-
ment (87), a considerably smaller proportion than that for
whom treatment has been recommended according to
published guidelines.
VII. CLINICAL EVALUATION
A. Minimum Evaluation of the Patient With AF
1. Clinical History and Physical Examination. The initial
evaluation of a patient with suspected or proven AF includes
characterizing the pattern of the arrhythmia as paroxysmal or
persistent, determining its cause, and defining associated car-
diac and extracardiac factors (Table 1). A careful history will
result in a well-planned, focused workup that serves as an
effective guide to therapy (2). The workup of an AF patient can
usually take place and therapy can be initiated in 1 outpatient
encounter. Delay occurs when the rhythm has not been
specifically documented and additional monitoring is neces-
sary.
The physical examination may suggest AF on the basis of
irregular pulse, irregular jugular venous pulsations, and
variation in the loudness of the first heart sound. Examina-
tion may also disclose associated valvular heart disease,
myocardial abnormalities, or HF. The findings on exami-
nation are similar in patients with atrial flutter, except that
the rhythm may be regular and rapid venous oscillations
may occasionally be visible in the jugular pulse.
2. Investigations. The diagnosis of AF requires ECG doc-
umentation by at least single-lead ECG recording during the
dysrhythmia, which may be facilitated by review of emergency
department records, Holter monitoring, or transtelephonic or
telemetric recordings. A portable ECG recording tool may
help establish the diagnosis in cases of paroxysmal AF and
provide a permanent ECG record of the dysrhythmia. If
episodes are frequent, then a 24-h Holter monitor can be used.
If episodes are infrequent, then an event recorder, which allows
the patient to transmit the ECG to a recording facility when
the arrhythmia occurs, may be more useful.
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B. Additional Investigation of Selected Patients With AF
Additional investigation may include Holter monitoring
and exercise testing, transesophageal echocardiography,
and/or electrophysiological study. See Table 1 for details.
VIII. MANAGEMENT
The major issues in management of patients with AF are
related to the arrhythmia itself and to prevention of throm-
boembolism. In patients with persistent AF, there are
fundamentally 2 ways to manage the dysrhythmia: to restore
and maintain sinus rhythm or to allow AF to continue and
ensure that the ventricular rate is controlled.
A. Rhythm Control vs Heart Rate Control
Reasons for restoration and maintenance of sinus rhythm in
patients with AF include relief of symptoms, prevention of
embolism, and avoidance of cardiomyopathy.
B. Cardioversion
1. Basis for Cardioversion of AF. Cardioversion is often
performed electively to restore sinus rhythm in patients with
Table 1. Minimum and Additional Clinical Evaluation of Patients With Atrial Fibrillation
Minimum evaluation
1. History and physical examination, to define
• The presence and nature of symptoms associated with AF
• The clinical type of AF (first episode, paroxysmal, persistent, or permanent)
• The onset of the first symptomatic attack or date of discovery of AF
• The frequency, duration, precipitating factors, and modes of termination of AF
• The response to any pharmacological agents that have been administered
• The presence of any underlying heart disease or other reversible conditions (eg, hyperthyroidism or
alcohol consumption)
2. Electrocardiogram, to identify
• Rhythm (verify AF)
• LV hypertrophy
• P-wave duration and morphology or fibrillatory waves
• Preexcitation
• Bundle-branch block
• Prior MI
• Other atrial arrhythmias
• To measure and follow the RR, QRS, and QT intervals in conjunction with antiarrhythmic drug
therapy
3. Chest radiograph, to evaluate
• The lung parenchyma, when clinical findings suggest an abnormality
• The pulmonary vasculature, when clinical findings suggest an abnormality
4. Echocardiogram, to identify
• Valvular heart disease
• Left and right atrial size
• LV size and function
• Peak RV pressure (pulmonary hypertension)
• LV hypertrophy
• LA thrombus (low sensitivity)
• Pericardial disease
5. Blood tests of thyroid function
• For a first episode of AF, when the ventricular rate is difficult to control, or when AF recurs
unexpectedly after cardioversion
Additional testing
• One or several tests may be necessary
1. Exercise testing
• If the adequacy of rate control is in question (permanent AF)
• To reproduce exercise-induced AF
• To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
2. Holter monitoring or event recording
• If diagnosis of the type of arrhythmia is in question
• As a means of evaluating rate control
3. Transesophageal echocardiography
• To identify LA thrombus (in the LA appendage)
• To guide cardioversion
4. Electrophysiological study
• To clarify the mechanism of wide-QRS-complex tachycardia
• To identify a predisposing arrhythmia such as atrial flutter or paroxysmal supraventricular tachycardia
• Seeking sites for curative ablation or AV conduction block/modification
AF indicates atrial fibrillation; LV, left ventricular; MI, myocardial infarction; RV, right ventricular; LA, left atrial; and AV,
atrioventricular. Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs (see Table 2).
1238 Fuster and Ryde´n, et al. JACC Vol. 38, No. 4, 2001
ACC/AHA/ESC Executive Summary October 2001:1231–65
persistent AF. The need for cardioversion can be immedi-
ate, however, when the arrhythmia is the main factor
responsible for acute HF, hypotension, or worsening of
angina pectoris in a patient with CAD. Nevertheless,
cardioversion carries a risk of thromboembolism unless
anticoagulation prophylaxis is initiated before the proce-
dure, and this risk appears to be greatest when the arrhyth-
mia has been present more than 48 h.
2. Methods of Cardioversion. Cardioversion can be
achieved by means of drugs or electrical shocks. Drugs were
commonly used before electrical cardioversion became a
standard procedure. The development of new drugs has
increased the popularity of pharmacological cardioversion,
although some disadvantages persist, including the risk of
drug-induced torsade de pointes ventricular tachycardia or
other serious arrhythmias. Pharmacological cardioversion is
still less effective than electrical cardioversion, but the latter
requires conscious sedation or anesthesia, whereas the
former does not.
The risk of thromboembolism or stroke does not differ
between pharmacological and electrical cardioversion. Thus,
recommendations for anticoagulation are the same for both
methods.
C. Pharmacological Cardioversion
Pharmacological cardioversion appears to be most effective
when initiated within 7 days after the onset of AF (88–91).
Most such patients have paroxysmal AF, a first-documented
episode of AF, or an unknown pattern of AF at the time of
treatment. (See Section III, Classification.) A large propor-
tion of patients with recent-onset AF experience spontane-
ous cardioversion within 24 to 48 h (92–94). This is less
likely to occur when AF has persisted for more than 7 days.
The relative efficacy of various drugs differs for pharma-
cological cardioversion of AF and atrial flutter, yet many
studies of drug therapy for AF have included patients with
atrial flutter. The dose, route, and rapidity of administration
influence efficacy. Reference is made to the Vaughan Wil-
liams classification of antiarrhythmic drugs (95), which has
been modified to include recently available drugs (Table 2).
A summary of recommendations is presented in Tables 10
through 12 (see Section IX-B, Recommendations for Phar-
macological and Electrical Cardioversion of AF, Tables
10–12). Although clinical use of the antiarrhythmic drugs
listed has been approved by regulatory agencies, therapeutic
use for AF has not been mentioned or approved in all cases
in each country. The recommendations given in this docu-
ment do not necessarily adhere to governmental regulations
and labeling requirements.
A frequent issue related to pharmacological cardioversion
is whether the antiarrhythmic drug should be started in the
hospital or on an outpatient basis. The major concern is the
potential for serious adverse effects, including torsade de
pointes ventricular tachycardia. With the exception of those
involving low-dose oral amiodarone (96), virtually all studies
of pharmacological cardioversion have been limited to
hospitalized patients.
D. Electrical Cardioversion
Direct-current cardioversion involves an electrical shock
synchronized with the intrinsic activity of the heart. This
ensures that electrical stimulation does not occur during the
vulnerable phase of the cardiac cycle (97).
Successful cardioversion of AF depends on the nature of
the underlying heart disease and the current density deliv-
ered to the atrial myocardium. The latter, in turn, depends
on the voltage of the defibrillator capacitor, the output
waveform, the size and position of the electrode paddles,
and transthoracic impedance.
In a randomized controlled study of 301 subjects under-
going elective external cardioversion, patients were allocated
to anterior-lateral (ventricular apex and right infraclavicular)
or anterior-posterior (sternum and left scapular) paddle
positions (98). The energy requirement was lower and
overall success was greater with the anterior-posterior con-
figuration (87%) than with the anterior-lateral alignment
(76%).
Cardioversion is performed with the patient having fasted
and under adequate anesthesia. Short-acting anesthetic
agents are preferred, because cardioversion patients are well
suited to day care and should recover rapidly after the
procedure (99).
An initial shock of 100 J is often too low, and an initial
energy of 200 J or greater is recommended for electrical
cardioversion of AF. Devices that deliver current with a
biphasic waveform appear to achieve cardioversion at lower
energy levels than those that use a monophasic waveform.
Table 2. Vaughan Williams Classification of Antiarrhythmic
Drug Actions
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Moricizine
Propafenone
Type II
Beta-blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Calcium-channel antagonists (e.g., verapamil and diltiazem)
Modified with permission from Vaughn Williams EM. A classification of antiar-
rhythmic action as reassessed after a decade of new drugs. J Clin Pharmacol
1984;24:129–47, © 1984 by Sage Publications Inc. (95) to include compounds
introduced after publication of the original classification.
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The primary success rate as measured 3 days after cardio-
version in 100 consecutive subjects was 86% (100); this
increased to 94% when the procedure was repeated during
treatment with quinidine or disopyramide. Only 23% of the
patients remained in sinus rhythm after 1 year and 16% after
2 years; in those who relapsed, repeated cardioversion with
antiarrhythmic medication resulted in sinus rhythm in 40%
and 33% after 1 and 2 years, respectively. For patients who
relapsed again, a third cardioversion resulted in sinus
rhythm in 54% at 1 year and 41% at 2 years. Thus, sinus
rhythm can be restored in a substantial proportion of
patients by direct-current cardioversion, but the rate of
relapse is high unless antiarrhythmic drug therapy is given
concomitantly.
Cardioversion of patients with implanted pacemaker and
defibrillator devices is safe when appropriate precautions are
taken. The device should be interrogated immediately
before and after cardioversion to verify appropriate function.
The paddles used for external cardioversion should be
positioned as distant as possible from the device, preferably
in the anterior-posterior configuration.
The risks of electrical cardioversion are mainly related to
embolic events and cardiac arrhythmias. Thromboembolic
events have been reported in 1% to 7% of patients who did
not receive anticoagulation before cardioversion (101,102).
Various brief arrhythmias might arise, especially ventricular
and supraventricular premature beats, bradycardia, and short
periods of sinus arrest (103). Ventricular tachycardia and
fibrillation can be precipitated in patients with hypokalemia
or digitalis intoxication (104,105). A slow ventricular re-
sponse to AF in the absence of drugs that slow AV nodal
conduction can indicate conduction defect. The patient
should be evaluated before cardioversion with these issues in
mind to avoid symptomatic bradycardia (106). Transient
ST-segment elevation can appear on the ECG after cardio-
version (107–108) and blood levels of creatine kinase-MB
can rise even without apparent myocardial damage.
Prophylactic drug therapy to prevent early recurrence of
AF should be considered individually for each patient.
Should relapse (particularly early relapse) occur, antiar-
rhythmic therapy is recommended in conjunction with the
second attempt. Further cardioversion is of limited value. In
highly symptomatic patients, infrequently repeated cardio-
version can be an acceptable approach.
E. Maintenance of Sinus Rhythm
1. Pharmacological Therapy to Prevent Recurrence of
AF. Maintenance of sinus rhythm is relevant in patients
with paroxysmal AF (in whom episodes terminate sponta-
neously) and persistent AF (in whom electrical or pharma-
cological cardioversion is necessary to restore sinus rhythm).
Whether paroxysmal or persistent, AF is a chronic disorder,
and recurrence is likely at some point in most patients (Fig.
4) (109,110). Prophylactic treatment with antiarrhythmic
drugs is therefore often necessary. The goal of maintenance
therapy is suppression of symptoms and sometimes preven-
tion of tachycardia-induced cardiomyopathy due to AF. It is
not yet known whether maintenance of sinus rhythm
prevents thromboembolism, HF, or death (80,111).
Recurrence of AF is not equivalent to treatment failure.
In several studies (112,113), patients with recurrent AF
often chose to continue drug treatment. Sometimes, reduc-
tion of the arrhythmia burden can constitute partial success,
whereas to other patients, any recurrence of AF may seem
intolerable. Nevertheless, most patients with AF eventually
experience recurrence. Risk factors for frequent recurrence
of paroxysmal AF (more than 1 episode per month) include
female sex and underlying heart disease (114). In persistent
AF, the 4-year arrhythmia-free survival was less than 10%
after single-shock electrical cardioversion without prophy-
lactic drug therapy (110). Predictors of recurrences within
that interval included hypertension, age greater than 55
years, and AF duration greater than 3 months. In that study,
serial cardioversions and prophylactic drug therapy resulted
in freedom from recurrent AF in only approximately 30% of
patients (110). Predictors of recurrence included age greater
than 70 years, AF duration greater than 3 months, and HF
(110).
2. General Approach to Antiarrhythmic Drug Therapy.
Before any antiarrhythmic agent is administered, reversible
cardiovascular and noncardiovascular precipitants of AF
should be addressed. Prophylactic drug treatment is seldom
indicated in case of a first-detected episode of AF and can
Figure 4. Arrhythmia-free survival after electrical cardioversion in patients
with persistent atrial fibrillation. The lower curve represents outcome after
a single shock when no prophylactic drug therapy was given. The upper
curve depicts the outcome with repeated electrical cardioversions in
conjunction with antiarrhythmic drug prophylaxis. ECV indicates electrical
cardioversion; SR, sinus rhythm. Reproduced with permission from van
Gelder et al., Arch Intern Med 1996;156:2585–92, © 1996, American
Medical Association (110).
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also be avoided in patients with infrequent and well-
tolerated paroxysmal AF. Similarly, when recurrences are
infrequent and tolerated, patients experiencing break-
through arrhythmias might not require a change in antiar-
rhythmic drug therapy. Beta-blockers can be effective in
patients who develop AF only during exercise, but few
patients have a single specific inciting cause for all episodes
of AF, and a majority will not sustain sinus rhythm without
antiarrhythmic drug treatment.
In patients with lone AF, a beta-blocker may be tried
first, but flecainide, propafenone, and sotalol are particularly
effective. Amiodarone and dofetilide are recommended as
alternative therapy. Quinidine, procainamide, and disopyr-
amide are not favored unless amiodarone fails or is contra-
indicated. The anticholinergic activity of long-acting diso-
pyramide makes this a relatively attractive choice for
patients with a predilection to vagally induced AF.
Propafenone is not recommended in vagally mediated AF
because its (weak) intrinsic beta-blocking activity might
aggravate this type of paroxysmal AF. In patients with
adrenergically mediated AF, beta-blockers represent first-
line treatment, followed by sotalol and amiodarone. In
patients with adrenergically mediated lone AF, amiodarone
should be chosen later in the sequence of drug therapy
because of its potential toxicity (see Fig. 11, Section IX).
Overall, when treatment with a single drug fails, combina-
tions of antiarrhythmic drugs may be tried. Useful combi-
nations include a beta-blocker, sotalol or amiodarone, plus a
type IC agent.
A drug that is initially safe might become proarrhythmic
when the patient develops CAD or HF or begins taking
other medication that in combination can be arrhythmo-
genic. Thus, the patient should be alerted to the potential
significance of such symptoms as syncope, angina pectoris,
or dyspnea and warned about the use of noncardiac drugs
that can prolong the QT interval. A useful source of
information is the Internet site http://www.torsades.org.
Monitoring of antiarrhythmic drug treatment varies with
the agent involved and with patient factors. Prospective trial
data on upper limits of drug-induced increases in QRS
duration or QT prolongation are not available. The follow-
ing recommendations are the consensus of the writing
committee. With type IC drugs, QRS widening should not
exceed 150% of the pretreatment QRS duration. Exercise
testing can be helpful to detect QRS widening that occurs
only at rapid heart rates (use-dependent conduction slow-
ing). For type IA or type III drugs, with the possible
exception of amiodarone, the corrected QT interval in sinus
rhythm should remain below 520 ms. During follow-up,
plasma potassium and magnesium levels and renal function
should be checked periodically, because renal insufficiency
leads to drug accumulation and predisposes to proarrhyth-
mia. In individual patients, serial noninvasive tests can be
appropriate to reevaluate LV function, especially if clinical
HF develops during treatment of AF.
3. Pharmacological Agents to Maintain Sinus Rhythm.
Fourteen controlled trials of drug prophylaxis involving
patients with paroxysmal AF have been published, and there
have been 22 published trials of drug prophylaxis for
maintenance of sinus rhythm in patients with persistent AF.
Comparative data are not sufficient to permit subclassifica-
tion by drug or etiology. Individual drugs and dosages for
maintenance of sinus rhythm are given in Table 3.
4. Out-of-Hospital Initiation of Antiarrhythmic Drugs
in Patients With AF. Recommendations for out-of-
hospital initiation or intermittent use of antiarrhythmic
drugs differ for patients with paroxysmal and persistent AF.
In patients with paroxysmal AF, the aims are to stop an
attack, to prevent recurrences, or a combination of both. In
patients with persistent AF, the aims of out-of-hospital
Table 3. Typical Doses of Drugs Used to Maintain Sinus Rhythm in Patients With
Atrial Fibrillation**
Drug* Daily Dosage Potential Adverse Effects
Amiodarone† 100–400 mg Photosensitivity, pulmonary toxicity, polyneuropathy,
GI upset, bradycardia, torsade de pointes (rare),
hepatic toxicity, thyroid dysfunction
Disopyramide 400–750 mg Torsade de pointes, HF, glaucoma, urinary retention,
dry mouth
Dofetilide‡ 500–1000 mcg Torsade de pointes
Flecainide 200–300 mg Ventricular tachycardia, congestive HF, enhanced AV nodal
conduction (conversion to atrial flutter)
Procainamide 1000–4000 mg Torsade de pointes, lupus-like syndrome, GI symptoms
Propafenone 450–900 mg Ventricular tachycardia, congestive HF, enhanced AV nodal
conduction (conversion to atrial flutter)
Quinidine 600–1500 mg Torsade de pointes, GI upset, enhanced AV nodal conduction
Sotalol‡ 240–320 mg Torsade de pointes, congestive HF, bradycardia,
exacerbation of chronic obstructive or bronchospastic
lung disease
GI indicates gastrointestinal; AV, atrioventricular; and HF, heart failure.
*Drugs are listed alphabetically.
**The drugs and doses given here have been determined by consensus based on published studies.
†A loading dose of 600 mg per day is usually given for one month or 1000 mg per day over 1 week.
‡Dose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
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drug initiation are to achieve pharmacological cardioversion
of AF, thereby obviating the need for electrical cardiover-
sion, or to enhance the success of electrical cardioversion
and prevent early recurrence of AF.
Few prospective data are available on the safety of
outpatient initiation of antiarrhythmic drug therapy. Proar-
rhythmia (Table 4) is rare in patients with normal ventric-
ular function and baseline QT intervals (41,115) without
profound bradycardia. As long as sinus or AV node dys-
function is not suspected, propafenone or flecainide may be
initiated out of hospital. Sudden death related to idiopathic
ventricular fibrillation in a structurally normal heart can
occur in patients with the Brugada syndrome, an inherited
cardiac disease characterized by ST-segment elevation in
the right precordial ECG leads and frequently accompanied
by right bundle-branch block. Type I antiarrhythmic drugs
can unmask this condition (116,117). Before therapy with
these agents is begun, a beta-blocker or calcium channel
antagonist should be given to prevent rapid AV conduction
or 1:1 AV conduction if atrial flutter develops (118–122).
Because termination of paroxysmal AF with flecainide or
propafenone can be associated with bradycardia due to sinus
node or AV node dysfunction, an initial conversion should be
undertaken in the hospital before a patient is declared fit for
outpatient “pill-in-the pocket” use of these agents for conver-
sion of recurrences. Out-of-hospital drug termination should
be avoided in patients with symptomatic sick sinus syndrome,
AV conduction disturbances, or bundle-branch block.
Sotalol may be initiated in outpatients with little or no
heart disease as long as the baseline uncorrected QT interval
is less than 450 ms, serum electrolytes are normal, and none
of the type III drug-related proarrhythmia risk factors are
present. Safety is greatest when sotalol is started when the
patient is in sinus rhythm. Amiodarone can usually be given
safely on an outpatient basis, even in patients with persistent
AF (123), but in-hospital loading might be more appropri-
ate when earlier restoration of sinus rhythm is needed, as in
patients with HF. Some loading regimens involve giving either
600 mg per day for 4 weeks (123) or greater than or equal to
1 g per day for 1 week (124) followed by lower maintenance
doses. Quinidine, procainamide, and disopyramide should
generally not be started out of hospital. An exception can be
made for disopyramide in patients without heart disease who
have a normal QT interval. Currently, the standards for use of
dofetilide do not permit out-of-hospital initiation.
Transtelephonic monitoring or other ECG surveillance
methods can be used to monitor conduction disturbances as
pharmacological antiarrhythmic therapy is initiated in pa-
tients with AF. Specifically, the PR interval (flecainide,
propafenone, sotalol, and amiodarone), QRS duration (fle-
cainide and propafenone), and QT interval (sotalol, amioda-
rone, and disopyramide) should be measured. As a general rule,
antiarrhythmic drugs should be started at a relatively low dose
with upward titration as needed, reassessing the ECG as each
dose change is made. The dose of other medication used for
rate control should be reduced approximately 6 weeks after
initiation of amiodarone and stopped if the rate slows exces-
sively. Concomitant drug therapies should be monitored
closely, and both the patient and the physician should be alert
to possible deleterious drug interactions.
5. Recurrence of AF After Cardioversion: Implications
for Drug Treatment. Although it has long been known
that most recurrences of AF occur within the first month
after electrical cardioversion, recent research with internal
atrial cardioversion (125) and day-to-day postconversion
studies (126) have established several patterns of recurrence
(Fig. 5). In some cases, there is complete failure of direct-
current countershock to elicit even a single isolated sinus or
ectopic atrial beat, tantamount to a high atrial defibrillation
threshold. In others, AF reappears within 1 to 2 minutes
after a period of sinus rhythm (127,128). Sometimes recur-
Table 4. Types of Proarrhythmia During Treatment With
Various Antiarrhythmic Drugs for Atrial Fibrillation or Atrial
Flutter According to the Vaughan Williams Classification
A. Ventricular proarrhythmia
c Torsade de pointes (VW type IA and type III drugs)
c Sustained monomorphic ventricular tachycardia (usually VW type
IC drugs)
c Sustained polymorphic ventricular tachycardia/VF without long QT
(VW types IA, IC, and III drugs)
B. Atrial proarrhythmia
c Provocation of recurrence (probably VW types IA, IC, and III drugs)
c Conversion of AF to flutter usually VW type IC drugs)
c Increase of defibrillation threshold (a potential problem with VW
type IC drugs)
C. Abnormalities of conduction or impulse formation
c Acceleration of ventricular rate during AF (VW type IA and type
IC drugs)
c Accelerate conduction over accessory pathway (digoxin, intravenous
verapamil or diltiazem)
c Sinus node dysfunction and atrioventricular block (almost all drugs)
VW indicates the Vaughan Williams classification of antiarrhythmic drugs (95). VF
indicates ventricular fibrillation; AF, atrial fibrillation.
Figure 5. Hypothetical illustration of cardioversion failure.Three types of
recurrences after electrical cardioversion of persistent AF are shown The
efficacy of drugs varies in enhancement of shock conversion and suppres-
sion of recurrences ECV indicates external cardioversion; IRAF, first
recurrence of AF after cardioversion. Modified with permission from Van
Gelder et al (129).
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rence is delayed from 1 day to 2 weeks (126) or more after
the shock. Complete shock failure and immediate recur-
rences occur in approximately 25% of patients undergoing
electrical cardioversion, and subacute recurrences occur in
about an equal proportion within 2 weeks (127).
Available data suggest that starting pharmacological ther-
apy before electrical cardioversion (Table 5) can enhance
immediate success and suppress early recurrences. As a
corollary, it seems appropriate to establish therapeutic
plasma drug concentrations at the time of cardioversion and
for a few weeks thereafter to optimize the chance of success.
After cardioversion to sinus rhythm, patients receiving
drugs that prolong QT interval should be observed in the
hospital for 24 to 48 h to evaluate the effects of heart rate
slowing and to allow prompt intervention in the event
torsade de pointes develops. Pharmacological agents may be
started out of hospital or in hospital immediately before
electrical cardioversion. The risks of pretreatment include
the possibility of a paradoxical increase in the defibrillation
threshold, as has occurred with flecainide (130); accelerated
ventricular rate during loading with type IA or IC drugs in
the absence of an AV nodal blocking agent (118–122,131)
and ventricular proarrhythmia (Table 4).
Pretreatment with pharmacological agents is most appro-
priate in patients who have previously failed to respond to
electrical cardioversion and in those who developed imme-
diate or subacute recurrence of AF. In patients with late
recurrence and those undergoing initial cardioversion of
persistent AF, pretreatment is optional (Fig. 10 and 11; see
Section IX).
6. Selection of Antiarrhythmic Agents in Patients
With Certain Cardiac Diseases.
A. HEART FAILURE. Patients with congestive HF are partic-
ularly prone to the ventricular proarrhythmic effects of
antiarrhythmic drugs. Randomized trials have demonstrated
the safety of amiodarone and dofetilide (given separately) in
patients with HF (132,133), and these are the recom-
mended drugs for maintenance of sinus rhythm (Fig. 11; see
Section IX).
B. CORONARY ARTERY DISEASE. In stable patients with
CAD, beta-blockers may be considered first, but their use is
supported by only 2 studies (134–135); data on their efficacy
for maintenance of sinus rhythm in patients with persistent
AF after cardioversion are not convincing (134). Sotalol has
substantial beta-blocking activity and can therefore be
chosen as the initial antiarrhythmic agent in AF patients
with ischemic heart disease, because it is associated with less
long-term toxicity than amiodarone (Fig. 11; see Section
IX). Both sotalol and amiodarone have reasonable short-
term safety profiles, and amiodarone might be preferred in
patients with HF (136 –138). Flecainide (139) and
propafenone are not recommended in these situations.
Quinidine, procainamide, and disopyramide are considered
third-line treatment choices in patients with CAD. Given
the results of the DIAMOND-MI trial (Danish Investiga-
tions of Arrhythmias and Mortality on Dofetilide in Myo-
cardial Infarction), dofetilide may be considered as a
second-line rather than a third-line antiarrhythmic agent,
but that study involved selected post-myocardial infarction
patients in whom the antiarrhythmic benefit balanced the
risk of proarrhythmic toxicity.
C. HYPERTENSIVE HEART DISEASE. Patients with LVH are
at increased risk of developing torsade de pointes related to
early ventricular afterdepolarizations (140–142). Thus, a
drug that does not prolong the QT interval is preferable as
first-line therapy, and in the absence of CAD or marked
ventricular hypertrophy, propafenone and flecainide are
reasonable choices (Fig. 11; Section IX). Amiodarone pro-
longs the QT interval but carries a very low risk of
ventricular proarrhythmia; its extracardiac toxicity profile
relegates it to second-line therapy in these individuals, but
Table 5. Pharmacological Treatment Before Cardioversion in Patients With Persistent Atrial Fibrillation: Effects of Various
Antiarrhythmic Drugs on Acute and Subacute Outcome of Transthoracic Direct Current Shock
Enhance Conversion
by DC Shock and
Prevent IRAF*
Suppress SRAF and
Maintenance Therapy Class
Recommendation
Class
Level of
Evidence
Effective Amiodarone
Flecainide
Ibutilide
Propafenone
Propafenone1verapamil
Quinidine
Sotalol
All drugs in recommendation Class I
(except ibutilide) plus beta-blockers
I B
Uncertain/unknown Beta-blockers
Disopyramide
Diltiazem
Dofetilide
Procainamide
Verapamil
Diltiazem
Dofetilide
Verapamil
IIb B
All drugs (except beta-blockers and amiodarone) should be initiated in hospital. IRAF indicates immediate recurrence of atrial fibrillation; SRAF, subacute recurrence of atrial
fibrillation; and DC, direct current.
*Drugs are listed alphabetically within each class of recommendation.
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amiodarone becomes first-line therapy when marked LVH
is present. When amiodarone and sotalol either fail or are
inappropriate, disopyramide, quinidine, or procainamide
can be used as alternatives.
D. WPW SYNDROME. Radiofrequency ablation of the acces-
sory pathway is the preferred therapy for patients with
preexcitation syndromes and AF, but antiarrhythmic drugs
might be useful. Digoxin should be avoided because of the
risk of paradoxical acceleration of the ventricular rate during
AF. Beta-blockers do not decrease conduction over acces-
sory pathways during preexcited periods of AF.
7. Nonpharmacological Correction of AF.
A. SURGICAL ABLATION. Based on mapping studies of ani-
mal and human AF, Cox et al (143–146) developed a
surgical procedure (maze operation) that controls AF in
more than 90% of selected patients. The exact mechanism
has not been established conclusively, but the creation of
barriers to conduction within the RA and LA limits the
amount of myocardium available to propagate reentrant
wave fronts, thereby inhibiting sustained AF. Incisions
encircling the pulmonary veins can prevent initiation of AF
by isolating potentially arrhythmogenic foci near the pul-
monary veins from the remainder of the atria or by isolating
atrial regions with the shortest refractory periods. Modifi-
cations of the Cox maze operation involve encircling the
pulmonary veins by surgical incisions within the LA and
radial incisions in both atria that join the mitral and
tricuspid valve annuli (147–149).
Surgical operations for AF have been successfully com-
bined with operative correction of a variety of structural
cardiac conditions. In patients with highly symptomatic AF
who require open heart operations for valvular, ischemic, or
congenital heart disease, consideration should be given to
concomitant maze operation for AF or flutter, although this
entails additional risk. The mortality rate of an isolated
maze operation is less than 1%, but mortality is higher when
the procedure is combined with other types of operative
repair. The morbidity associated with the maze operation
includes consequences common to median sternotomy and
cardiopulmonary bypass, as well as a risk of short-term fluid
retention (owing to reduced release of atrial natriuretic
peptide), transient reduction in LA and RA transport
function, and early postoperative atrial tachyarrhythmias. In
addition, when the blood supply to the sinus node is
disrupted, sinus node dysfunction might require permanent
pacemaker implantation. Progressive iterations of these
operations have reduced the risk of this complication to less
than 10%.
B. CATHETER ABLATION. Based on the success of surgical
approaches to AF, several catheter ablation strategies have
been designed to produce similar effects (150–152). Abla-
tion strategies limited to the RA produce marginal improve-
ment (150), whereas linear ablation in the LA has been
more successful. The recognition that foci triggering AF
often originate within the pulmonary veins has led to
ablation strategies that target this zone or electrically isolate
the pulmonary vein from the LA. Other sites of arrhyth-
mogenic foci have been found in the superior vena cava, the
RA and LA, and the coronary sinus. Ablation of these foci
eliminates or reduces the frequency of recurrent AF in more
than 60% of patients, but the risk of recurrent AF after a
focal ablation procedure is still 30% to 50% over the first
year and even higher when more than 1 pulmonary vein is
involved. Thus, many patients continue to require antiar-
rhythmic drug therapy after ablative therapy of AF (153).
Potential complications of catheter ablation for AF include
systemic embolism, pulmonary vein stenosis, pericardial
effusion, cardiac tamponade, and phrenic nerve paralysis.
Thus, although these procedures have produced promising
results, they have not yet been widely applied.
Atrial flutter can develop not only as a distinct arrhythmia
but also during antiarrhythmic drug therapy of AF, espe-
cially with type IC agents. Catheter ablation is more
effective than antiarrhythmic drugs for treatment of atrial
flutter, reducing the recurrence rate from 93% to 5% when
used as first-line therapy (37). In addition, the risk of
developing AF might also be lower after catheter ablation of
atrial flutter than with pharmacological therapy (29% vs
60% over the first year).
C. SUPPRESSION OF AF BY PACING. Although atrium-based
pacing is associated with a lower risk of AF and stroke than
ventricle-based pacing for patients requiring pacemakers for
bradyarrhythmias, the use of pacing as a primary therapy for
prevention of recurrent AF has not been validated.
D. INTERNAL ATRIAL CARDIOVERTER/DEFIBRILLATORS.
There has been an interest in internal cardioversion of AF
for the past 10 years. Attempts have been made to find
shock waveforms that reduce the energy requirements for
cardioversion, making the shock tolerable to awake patients.
One cardioverter (154) capable of atrial sensing and cardio-
version as well as ventricular sensing and pacing was
evaluated in 290 AF patients. The conversion rate to sinus
rhythm was 93%. Another device, with dual-chamber sens-
ing, pacing, and cardioversion/defibrillation capabilities and
a maximum output of 27 J, is a ventricular defibrillator with
atrial cardioversion capabilities. It was designed to treat
both atrial and ventricular arrhythmias with pacing modal-
ities before delivering low-energy shocks. Potential candi-
dates for atrial cardioverter/defibrillators, mainly those with
infrequent episodes of poorly tolerated AF, are often suit-
able for catheter ablation.
F. Rate Control During AF
1. Pharmacological Approach. An alternative to mainte-
nance of sinus rhythm in patients with paroxysmal or
persistent AF is control of the ventricular rate. In a recent
randomized trial, the therapeutic strategies of rate versus
rhythm control yielded similar clinical results with respect to
symptoms in patients with AF, but exercise tolerance was
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better with rhythm control (111). The results of other
studies comparing these 2 strategies are not yet available
(80). The rate is generally considered controlled when the
ventricular response is between 60 and 80 bpm at rest and
between 90 to 115 bpm during moderate exercise (156,157).
Heart rate variability during AF provides additional infor-
mation about the status of the autonomic nervous system,
which might have independent prognostic implications
(158–161).
Negative chronotropic therapy of AF is based mainly on
depression of conduction across the AV node. Sinus brady-
cardia and heart block occur in some patients with parox-
ysmal AF, particularly the elderly, as an unwanted effect of
pharmacological intervention with beta-blockers, digitalis
glycosides, or calcium channel antagonists. Table 6 outlines
agents that may be administered to control the ventricular
response to AF in an emergency setting. Table 7 outlines
drugs that block AV nodal conduction; these drugs can be
used to achieve rate control both at rest and during exercise
or other types of cardiovascular stress. A combination of
drugs is often necessary to achieve rate control in AF
patients in the acute and chronic settings. Therapy often
requires careful dose titration, and some patients develop
symptomatic bradycardia that requires permanent pacing.
2. Nonpharmacological Regulation of AV Nodal Con-
duction and Pacing. Because ventricular pacing prolongs
the AV nodal refractory period as a result of concealed
retrograde penetration, it eliminates ventricular cycles
longer than the pacing cycle length and reduces the number
of short ventricular cycles related to rapid AV conduction
during AF. As a result, ventricular pacing can be used as a
strategy to reduce the irregularity of the ventricular rhythm
(162). This modality can be useful for patients with marked
variability in ventricular rates and for those who develop
Table 6. Intravenous Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation
Drug* Loading Dose Onset Maintenance Dose Major Side Effects
Class
Recommendation
Diltiazem 0.25 mg/kg IV over 2 min 2–7 min 5–15 mg per hour infusion Hypotension, heart block, HF I†
Esmolol‡ 0.5 mg/kg over 1 min 5 min 0.05–0.2 mgzkg21zmin21 Hypotension, heart block,
bradycardia, asthma, HF
I
Metoprolol‡ 2.5–5 mg IV bolus over 2 min; up
to 3 doses
5 min NA Hypotension, heart block,
bradycardia, asthma, HF
I†
Propranolol‡ 0.15 mg/kg IV 5 min NA Hypotension, heart block,
bradycardia, asthma, HF
I†
Verapamil 0.075–0.15 mg/kg IV over 2 min 3–5 min NA Hypotension, heart block, HF I†
Digoxin 0.25 mg IV each 2 h, up to 1.5 mg 2 h 0.125–0.25 mg daily Digitalis toxicity, heart block,
bradycardia
IIb**
HF indicates heart failure.
*Drugs are listed alphabetically within each class of recommendation.
**Type I in congestive HF.
†Type IIb in congestive HF.
‡Only representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this indication in appropriate
doses.
Table 7. Recommendations for Use of Orally Administered Pharmacological Agents for Heart Rate Control in Patients With
Atrial Fibrillation
Drug* Loading Dose Onset Usual Maintenance Dose** Major Side Effects Recommendation
Digoxin 0.25 mg PO each 2 h;
up to 1.5 mg
2 h 0.125–0.375 mg daily Digitalis toxicity, heart block, bradycardia I
Diltiazem NA 2–4 h 120–360 mg daily in divided
doses; slow release
available
Hypotension, heart block, HF I
Metoprolol† NA 4–6 h 25–100 mg BID Hypotension, heart block, bradycardia,
asthma, HF
I
Propranolol† NA 60–90 min 80–240 mg daily in divided
doses
Hypotension, heart block, bradycardia,
asthma, HF
I
Verapamil NA 1–2 h 120–360 mg daily in divided
doses; slow release
available
Hypotension, heart block, HF, digoxin
interaction
I
Amiodarone 800 mg daily for 1 wk
600 mg daily for 1 wk
400 mg daily for 4–6 wk
1–3 wk 200 mg daily Pulmonary toxicity, skin discoloration,
hypothyroidism, corneal deposits, optic
neuropathy, warfarin interaction,
proarrhythmia
IIb
HF indicates heart failure; PO, by mouth; NA, not applicable; HF, heart failure; and BID, twice a day.
*Drugs are listed alphabetically within each class of recommendation.
**Recommended maintenance dosages are the usual ones necessary, but higher doses may be appropriate in some patients.
†The table includes representative members of the type of beta-blocker drugs, but other, similar agents could be used for this indication in appropriate doses.
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resting bradycardia during treatment with medications pre-
scribed to control rapid ventricular rates with exertion. The
precise role of pacemaker therapy to regulate the ventricular
rate in patients with AF, however, remains controversial.
3. Nonpharmacological/AV Nodal Ablation. AV nodal
ablation and permanent pacemaker implantation are highly
effective means of improving symptoms in patients with AF
who experience symptoms related to a rapid ventricular rate
during AF that cannot be adequately controlled with anti-
arrhythmic or negative chronotropic medications
(83,84,86,163). AV nodal ablation is especially useful when
an excessive ventricular rate induces a tachycardia-mediated
decline in ventricular systolic function despite appropriate
medical therapy.
The limitations of AV nodal ablation include the persis-
tent need for anticoagulation, loss of AV synchrony, and
lifelong pacemaker dependency. There is a small but real
risk of sudden death, largely due to torsade de pointes (164).
In addition, ablation of the AV conduction system might
preclude or limit the later use of newer nonpharmacological
treatments. Patients with impaired diastolic ventricular com-
pliance who are most dependent on AV synchrony for main-
tenance of cardiac output (such as HCM or restrictive cardio-
myopathies) might experience persistent symptoms after AV
nodal ablation and permanent pacemaker implantation. Thus,
patients must be counseled regarding each of these consider-
ations before proceeding with this irreversible treatment.
The use of catheter ablation to modify AV nodal con-
duction by eliminating posterior atrial inputs to the AV
node has been reported to decrease the ventricular rate
during AF and to improve cardiac symptoms without
requiring pacemaker implantation (165,166). This tech-
nique has several limitations, including the inadvertent
induction of complete AV block and a relatively high risk of
increasing ventricular rate over the first 6 months after
ablation. Thus, AV nodal modification without pacemaker
implantation is only rarely used for patients with rapid
ventricular rates during AF.
G. Preventing Thromboembolism
1. Risk Stratification.
A. EPIDEMIOLOGICAL DATA. The rate of stroke in patients
with AF is related to coexistent cardiovascular disease
(4,19,73,74). In a small, retrospective, population-based
study in Olmsted County, Minnesota, over 3 decades, the
15-year cumulative stroke rate in people with lone AF
(defined as those younger than age 60 years with no clinical
history or echocardiographic signs of cardiopulmonary dis-
ease) was 1.3% per year (4). Conversely, in the Framingham
Study, the age-adjusted stroke rate over a mean follow-up
period of 11 years was 28.2% in those with lone AF, which
was more liberally defined to include patients with a history
of hypertension or cardiomegaly on chest roentgenography;
by comparison, the rate was 6.8% in normal controls. In the
SPAF study, the annualized rate of ischemic stroke was
similar in those with recurrent (3.2%) and permanent (3.3%)
AF (167). Those with prior stroke or transient ischemic
attack have a rate of subsequent stroke of 10% to 12% per
year despite aspirin use and benefit substantially from
treatment with adjusted-dose oral anticoagulation
(168,169). In addition to prior thromboembolism, indepen-
dent risk factors for ischemic stroke in nonvalvular AF
include HF, hypertension, increasing age, and diabetes
mellitus (19,73,170 –172). Female sex, blood pressure
greater than 160 mmHg, and LV dysfunction have each
been linked to stroke (75,170,173). The relative risk for
ischemic stroke associated with specific clinical features is
given in Table 8. Nearly half of AF-associated strokes occur
in patients greater than 75 years old, and AF is the most
frequent cause of disabling stroke in elderly women
(9,171,173). Older people are at increased risk for
anticoagulant-related bleeding (174) and are therefore less
likely to be treated with oral anticoagulation, even in
situations for which it has been proven efficacious (175).
Special consideration of the elderly is therefore warranted
for effective stroke prophylaxis (171).
Patients with AF related to thyrotoxicosis, which is often
associated with congestive HF, are also at increased risk for
stroke (176–178), although the underlying mechanism is
not clear (52,179,180). AF is a frequent complication of
HCM (181), and such patients have an incidence of stroke
and systemic embolism amounting to 2.4% to 7.1% per year
(182–185).
B. ROLE OF ECHOCARDIOGRAPHY IN RISK STRATIFICATION.
Transthoracic Echocardiography In a meta-analysis of 3
randomized trials of antithrombotic therapy, moderate to
severe LV dysfunction was the only independent echocar-
diographic predictor of stroke in patients with AF when
clinical features were also considered (186). The diameter of
the LA was a less useful predictor of ischemic events (186).
Transesophageal Echocardiography TEE is the most sen-
sitive and specific imaging technique for detection of LA
and LA appendage (LAA) thrombus, far surpassing trans-
thoracic echocardiography (52). This modality also permits
superior evaluation for other causes of cardiogenic embolism
(187) and superiority in measuring LAA function (188).
Table 8. Risk Factors for Ischemic Stroke and Systemic
Embolism in Patients With Nonvalvular Atrial Fibrillation
Risk Factors (Control Groups)
Relative
Risk
Previous stroke or TIA 2.5
History of hypertension 1.6
Congestive heart failure 1.4
Advanced age (continuous, per decade) 1.4
Diabetes mellitus 1.7
Coronary artery disease 1.5
TIA indicates transient ischemic attack. Relative risk refers to comparison with atrial
fibrillation patients without these risk factors. As a group, patients with nonvalvular
atrial fibrillation have about a 6-fold increased risk of thromboembolism compared
with patients in normal sinus rhythm. Data from collaborative analysis of five primary
prevention trials (75).
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Several TEE features have been associated with thrombo-
embolism, including such LA/LAA abnormalities as
thrombus, reduced flow velocity, and spontaneous echo
contrast, as well as complex atheromatous plaques in the
aorta (70,189).
Detection of LA/LAA thrombus stands as a contraindi-
cation to elective cardioversion of AF. The absence of
detectable thrombus does not preclude thromboembolism
after cardioversion if patients do not receive anticoagulation
therapy (190,191). A TEE-guided strategy for elective
cardioversion of AF has been reported to result in compa-
rable outcomes for thromboembolism and death compared
with conventional anticoagulation for 3 weeks before and 4
weeks after cardioversion (192). Hence, transthoracic echo-
cardiography is valuable for defining the origin of AF (eg, to
detect rheumatic mitral valve disease or HCM), and TEE
can provide additional information for stratifying thrombo-
embolic risk. Three clinical schemes have been proposed
recently to stratify the risk of ischemic stroke in AF patients
that are directly or indirectly based on analyses of prospec-
tively monitored cohorts of participants in clinical trials in
which antithrombotic therapy was controlled (172,186,
193). One set of criteria is based on multivariate pooled
analysis of 1593 participants assigned to the control or
placebo groups of 5 randomized primary prevention trials in
which 106 ischemic strokes occurred over a mean follow-up
of 1.4 years (19). This scheme divides patients into 2 strata,
distinguishing low-risk patients from those at intermediate
or high risk. Echocardiographic features were not consid-
ered initially, but subsequent analysis of 3 of these trials
identified abnormal LV systolic function as an independent
predictor of stroke (186). The SPAF study criteria were
based on multivariate analysis of 854 participants assigned
aspirin in the SPAF-I and -II clinical trials who were
followed up for a mean of 2.3 years, during which 68
ischemic strokes were observed. A third set of criteria was
developed by expert consensus (193) based on consideration
of the 2 foregoing schemes and other available data to
classify patients into low-, intermediate-, and high-risk
groups (Table 9).
C. THERAPEUTIC IMPLICATIONS. The risk of thromboem-
bolism for patients with chronic atrial flutter is generally
estimated as higher than for patients with sinus rhythm but
less than for those with persistent or permanent AF. Biblo
et al. (196) recently reviewed 8 years of retrospective data on
749,988 hospitalized older patients, including 17,413 with
atrial flutter and 337,428 with AF. The overall stroke risk
ratio for patients with atrial flutter was 1.4 compared with
the control group; for patients with AF, the relative risk was
1.6. As a chronic arrhythmia, atrial flutter is uncommon,
and the risk of thromboembolism is not as well established
as it is for AF. Until more robust data become available, and
although the overall thromboembolic risk associated with
atrial flutter can be lower than with AF, it seems prudent to
estimate risk by use of similar stratification criteria.
2. Antithrombotic Strategies for Prevention of Ischemic
Stroke and Systemic Embolism. Five large randomized
trials published between 1989 and 1992 evaluated oral
anticoagulation, and 2 tested aspirin for primary prevention
of thromboembolism in patients with nonvalvular AF
(24,197–199). A sixth trial focused on secondary prevention
among patients who had survived nondisabling stroke or
transient cerebral ischemic attack (169). Meta-analysis ac-
cording to the principle of intention to treat showed that
adjusted-dose oral anticoagulation is highly efficacious for
prevention of all stroke (both ischemic and hemorrhagic),
with a risk reduction of 61% (95% CI 47% to 71%) vs
placebo (200) (Fig. 6). This reduction was similar for both
primary and secondary prevention. The duration of
follow-up in these trials was generally between 1 and 2
years; the longest was 2.2 years, whereas in clinical practice,
the need for antithrombotic therapy typically extends over
much longer periods.
Table 9. Published Risk-Stratification Schemes for Primary* Prevention of Thromboembolism in Patients With Nonvalvular
Atrial Fibrillation
Source High Risk Intermediate Risk Low Risk
Atrial Fibrillation Investigators (194)† Age greater than or equal to 65 years
History of hypertension
Coronary artery disease
Diabetes
Age less than 65 years
No high-risk features
American College of Chest Physicians (193) Age greater than 75 years
History of hypertension
Left ventricular dysfunction‡
More than 1 intermediate risk factor
Age 65–75 years
Diabetes
Coronary artery disease
Thyrotoxicosis
Age less than 65 years
No risk factors
Stroke Prevention in Atrial Fibrillation (186) Women greater than 75 years
Systolic BP greater than 160 mm Hg
Left ventricular dysfunction†
History of hypertension
No high-risk features
No high-risk features
No history of hypertension
BP indicates blood pressure. Patients are classified on the basis of the presence or absence of any risk factor.
Adapted with permission from Am J Med, Vol. 109, Pearce et al., Assessment of these schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation, pp.
45–51, © 2000, with permission, from Excerpta Medica, Inc. (195).
*Patients with AF and prior thromboembolism are at high risk of stroke, and anticoagulation is indicated for secondary prevention in such cases.
†Did not distinguish high-risk from intermediate-risk patients.
‡Left ventricular dysfunction refers to moderate to severe wall motion abnormality assessed globally by 2-dimensional echocardiography, reduced ejection fraction, fractional
shortening less than 0.25 by M-mode echocardiography, or clinical heart failure.
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Patient age and the intensity of anticoagulation are the
most powerful predictors of major bleeding (201–204). Trial
participants, at an average age of 69 years, were carefully
selected and managed. It is thus unclear whether the
relatively low rates of major hemorrhage also apply to AF
patients in clinical practice, who have a mean age of
approximately 75 years and whose anticoagulation therapy is
less closely regulated (205,206).
The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
hemorrhagic complications. It is important to target the
lowest adequate intensity of anticoagulation to minimize the
risk of bleeding, particularly for elderly AF patients. Max-
imum protection against ischemic stroke in AF is probably
achieved with an international normalized ratio (INR) of 2
to 3 (168,207,208), whereas an INR range of 1.6 to 2.5
appears to be associated with incomplete efficacy, estimated
at approximately 80% of that achieved with higher intensity
anticoagulation (Fig. 7) (207,209).
In patients with AF who do not have mechanical valves,
it is the consensus of the writing group that anticoagulation
can be interrupted for a period of up to 1 week for
procedures that carry a risk of bleeding, without substituting
heparin. In high-risk patients, or when a series of proce-
dures requires interruption for a period longer than 1 week,
unfractionated or low-molecular-weight heparin can be
administered intravenously or subcutaneously, respectively.
Low-molecular-weight heparins have several pharmaco-
logical advantages over unfractionated heparin. These in-
clude a longer half-life, more predictable bioavailability
(greater than 90% after subcutaneous injection), predictable
clearance (enabling once- or twice-daily subcutaneous ad-
ministration), and predictable antithrombotic response
based on body weight, which permits fixed-dose treatment
without laboratory monitoring except under special circum-
stances, such as obesity, renal insufficiency, or pregnancy
(210). Low-molecular-weight heparins carry a lower risk of
heparin-induced thrombocytopenia than unfractionated
heparin (211). Self-administration of low-molecular-weight
heparins out of hospital is a promising approach that can
result in cost savings in conjunction with elective cardiover-
sion (212).
Aspirin offers only modest protection against stroke for
patients with AF (Fig. 8). The effect is less consistent than
that of oral anticoagulation (200,213). Aspirin might be
more efficacious for AF patients with hypertension or
diabetes (213,214) and for reducing noncardioembolic ver-
sus cardioembolic ischemic strokes (49). Cardioembolic
Figure 6. Antithrombotic therapy for prevention of stroke (ischemic and
hemorrhagic) in patients with nonvalvular AF: adjusted-dose warfarin
compared with placebo. Adapted with permission from Hart et al.
(170,200) Ann Intern Med 1999;131:492–501. (The American College of
Physicians–American Society of Internal Medicine is not responsible for
the accuracy of the translation.)
Figure 7. Adjusted odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation in randomized trials of antithrombotic
therapy for patients with AF. The data are from Hylek et al (203,207).
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strokes are, on average, more disabling than noncardioem-
bolic strokes (69).
3. Conversion to Sinus Rhythm and Thromboembolism.
Randomized studies of antithrombotic therapy are lacking
for patients undergoing cardioversion of AF or atrial flutter,
but the risk of thromboembolism was between 1% and 5%
in case-control series (102,215). There is no solid clinical
evidence that cardioversion of AF followed by prolonged
maintenance of sinus rhythm effectively reduces thrombo-
embolism. Patients in whom LAA thrombus is identified by
TEE appear to be at high risk of thromboembolism after
cardioversion of AF or flutter, and they should be treated
with anticoagulation for at least 3 to 4 weeks before and
after either pharmacological or electrical cardioversion.
In a multicenter study (192), 1222 patients with either
AF persisting longer than 2 days or atrial flutter and
previous AF were randomized to a TEE-guided or conven-
tional strategy. One group received anticoagulation with
heparin just before and with warfarin for 4 weeks after
cardioversion. When thrombus was identified, cardioversion
was postponed, and warfarin was administered for 3 weeks
before TEE was repeated. The other group received anti-
coagulant therapy for 3 weeks before and 4 weeks after
cardioversion. Both approaches were associated with a
comparably low risk of stroke (0.8% with the TEE-guided
approach and 0.5% with the conventional approach) after 8
weeks of follow-up. The risk of major bleeding did not differ
significantly. There were no differences in the proportion of
subjects in whom sinus rhythm was successfully restored.
Thus, the clinical benefit of the TEE approach was limited
to saving time before cardioversion.
Conversion of AF to sinus rhythm results in transient
mechanical dysfunction of the LA and LAA (190), known
as “stunning.” This occurs after spontaneous, pharmacolog-
ical (216,217), or electrical (217–219) conversion of AF and
after radiofrequency catheter ablation of atrial flutter (220).
The loss of atrial function can be associated with spontane-
ous echo contrast (190). Recovery of mechanical function
can be delayed for several weeks, depending in part on the
duration of AF before restoration of sinus rhythm (221–
223). This could explain why some patients with no
demonstrable LA thrombus on TEE before cardioversion
subsequently experience thromboembolic events (191). Pre-
sumably, thrombus forms during the period of stunning and
is expelled after the return of mechanical function, which
explains the clustering of thromboembolic events in the first
10 days after cardioversion (224).
Anticoagulation is recommended for 3 to 4 weeks before
and after cardioversion for patients with AF of unknown
duration or that has lasted more than 48 h. Although LA
thrombus and systemic embolism have been documented in
patients with AF of shorter duration, the need for antico-
agulation in such patients is less clear. When acute AF
produces hemodynamic instability, immediate cardiover-
sion should not be delayed, but intravenous heparin or
low-molecular-weight heparin should be administered
first. Protection against late embolism might require
continuation of anticoagulation; the duration of antico-
agulation after the procedure depends on the likelihood
that AF will recur and on the patient’s intrinsic risk of
thromboembolism.
IX. PROPOSED MANAGEMENT STRATEGIES
A. Overview of Algorithms for Management of Patients
With AF
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or perma-
nent) and decisions about restoration and maintenance of
sinus rhythm, control of the ventricular rate, and anticoag-
Figure 8. Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular AF: warfarin compared with aspirin
and aspirin compared with placebo. Adapted with permission from Hart et al. (170,200) Ann Intern Med 1999;131:492–501. (The American College of
Physicians–American Society of Internal Medicine is not responsible for the accuracy of the translation.)
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ulation. These issues are addressed in the various manage-
ment algorithms for each presentation of AF.
1. Newly Discovered or First Episode of AF (Fig. 9). It is
not always clear whether the initial presentation of AF is
actually the patient’s first episode, particularly in those with
minimal or no symptoms of the dysrhythmia, so both are
considered together. In patients who have self-limited
episodes of paroxysmal AF, antiarrhythmic drugs to prevent
recurrence are usually unnecessary, unless AF is associated
with severe symptoms related to hypotension, myocardial
ischemia, or HF. Whether these individuals require long-
term or even short-term anticoagulation is not clear, and the
decision must be individualized for each patient based on
the intrinsic risk of thromboembolism.
In patients with persistent AF, one option is to accept
progression to permanent AF, with attention to antithrom-
botic therapy and control of the ventricular rate. Although it
might seem reasonable to make at least 1 attempt to restore
sinus rhythm, this is not in the best interest of all patients.
An example is the older man without risk factors for
thromboembolism in whom asymptomatic AF is discovered
on routine examination and control of the ventricular rate is
readily achieved. Here, the potential toxicity of antiarrhyth-
mic drugs might outweigh the benefit of restoration of sinus
rhythm. If the decision is made to attempt to restore and
maintain sinus rhythm, anticoagulation and rate control are
important before cardioversion. Although long-term anti-
arrhythmic therapy might not be needed to prevent recur-
rent AF after cardioversion, short-term therapy might be
beneficial. In patients with AF of more than 3 months’
duration, early recurrence is common after cardioversion.
Antiarrhythmic medication can be initiated before cardio-
version (after adequate anticoagulation) in such cases to
reduce the likelihood of recurrence, and the duration of drug
therapy would be brief (eg, 1 month).
2. Recurrent Paroxysmal AF (Fig. 10 and 11). In patients
who experience brief or minimally symptomatic recurrences
of paroxysmal AF, it is reasonable to avoid antiarrhythmic
drugs, but troublesome symptoms generally call for suppres-
sive antiarrhythmic therapy. Rate control and prevention of
thromboembolism are appropriate in both situations. In any
given patient, several different antiarrhythmic drugs might
be effective, and the initial selection is thus based mainly on
safety. For individuals with no or minimal structural heart
disease, flecainide, propafenone, and sotalol are recom-
mended as initial antiarrhythmic therapy because they are
generally well tolerated and are essentially devoid of extra-
cardiac organ toxicity. When one or another of these drugs
is ineffective or is associated with side effects, then second or
third line choices include amiodarone, disopyramide, pro-
cainamide, and quinidine, which have greater potential for
adverse reactions. A nonpharmacological approach is appro-
priate for some patients, and this should be considered
before amiodarone therapy is begun. Occasionally, a con-
sistent initiating factor can be found. Disopyramide or
flecainide may be used in cases of vagally mediated AF,
Figure 9. Pharmacological management of patients with newly discovered AF. AF indicates atrial fibrillation; HF, heart failure.
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whereas beta-blockers or sotalol is suggested as the initial
agent for adrenergically induced AF.
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension,
although other types of heart disease can also be associated
with AF. For patients with HF, safety data support the
selection of amiodarone or dofetilide to maintain sinus rhythm.
Patients with ischemic heart disease often require beta-blocker
medication. Then sotalol, a drug with both beta-blocking
activity and primary antiarrhythmic efficacy, is considered first
unless the patient has HF. Amiodarone and dofetilide are
considered secondary agents in this situation. The clinician
may consider disopyramide, procainamide, or quinidine on an
individual basis. In patients with hypertension without LVH,
drugs such as flecainide and propafenone, which do not
prolong repolarization and the QT interval, might offer a safety
advantage and are recommended first. If these agents either
prove ineffective or produce side effects, then amiodarone,
dofetilide, and sotalol represent appropriate secondary choices.
Disopyramide, procainamide, and quinidine are considered
third-line agents in this situation. Hypertrophied myocardium
is prone to proarrhythmic toxicity and development of the
torsade de pointes type of ventricular tachycardia. Amiodarone
is suggested as first-line therapy in patients with LVH (wall
thickness greater than or equal to 1.4 cm) on the basis of its
relative safety compared with several other agents. Because
neither ECG nor echocardiography invariably detects LVH as
defined by measurement of myocardial mass, clinicians face a
conundrum. The selection of antiarrhythmic drugs for patients
with a history of hypertension is compounded by the dearth of
prospective controlled trials comparing the safety and efficacy
of drug therapy for AF.
The scarcity of data from randomized trials of antiar-
rhythmic medications for treatment of patients with AF
applies generally to all patient groups. Accordingly, the
drug-selection algorithm presented here has been developed
as a consensus of experts and is particularly subject to
revision as additional evidence emerges in this field (Fig.
10).
3. Recurrent Persistent AF (Fig. 11 and 12). Patients with
minimal symptoms who have undergone at least 1 attempt
to restore sinus rhythm can remain in AF with therapy for
rate control and prevention of thromboembolism. Alterna-
tively, those with symptoms favoring sinus rhythm should be
treated with an antiarrhythmic agent (in addition to medica-
tions for rate control and anticoagulation) before cardioversion.
The selection of an antiarrhythmic drug should be based on the
same algorithm used for patients with recurrent paroxysmal
AF.
4. Permanent AF (Fig. 12). Permanent AF is the desig-
nation given to cases in which sinus rhythm cannot be
sustained after cardioversion of AF or when the patient and
physician have decided to allow AF to continue without
further efforts to restore sinus rhythm. It is important to
maintain control of the ventricular rate and to use anti-
thrombotic therapy, as outlined elsewhere in this document,
for all patients in this category.
B. Recommendations for Management of Patients With AF
Recommendations are evidence based and are derived pri-
marily from published data. The weight of evidence was
ranked highest (A) when the data were derived from
multiple randomized clinical trials and intermediate (B)
when the data were derived from a limited number of
randomized trials, nonrandomized studies, or observational
registries. A lower rank (C) was given when the primary
basis for the recommendation was expert consensus.
Recommendations follow the format of previous ACC/
AHA guidelines for classifying indications, summarizing
both the evidence and expert opinion:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure
or treatment is useful and effective.
Class II: Conditions for which there is conflicting ev-
idence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: The weight of evidence or opinion
is in favor of the procedure or
treatment.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence or opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure or
treatment is not useful/effective and in some
cases can be harmful.
The reader is referred to the full-text guidelines available
on the ACC (www.acc.org), AHA (www.americanheart.
org), ESC (www.escardio.org), and NASPE (www.naspe.
org) World Wide Web sites and published in the European
Heart Journal in mid-October 2001 for a complete descrip-
Figure 10. Pharmacological management of patients with recurrent par-
oxysmal AF. *See Figure 11 for suggested drugs.
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tion of the rationale and evidence supporting these recom-
mendations.
RECOMMENDATIONS FOR
PHARMACOLOGICAL AND
ELECTRICAL CARDIOVERSION OF AF
Class I
1. Immediate electrical cardioversion in patients with
paroxysmal AF and a rapid ventricular response
who have ECG evidence of acute MI or symptom-
atic hypotension, angina, or HF that does not
respond promptly to pharmacological measures.
(Level of Evidence: C)
2. Cardioversion in patients without hemodynamic
instability when symptoms of AF are unacceptable.
(Level of Evidence: C)
Class IIa
1. Pharmacological or electrical cardioversion to ac-
celerate restoration of sinus rhythm in patients with
a first-detected episode of AF. (Level of Evidence: C)
(See Tables 10 through 12 for recommended drugs.)
2. Electrical cardioversion in patients with persistent
AF when early recurrence is unlikely. (Level of
Evidence: C)
3. Repeated cardioversion followed by prophylactic
drug therapy in patients who relapse to AF without
antiarrhythmic medication after successful cardio-
version. (Level of Evidence: C)
Class IIb
1. Pharmacological agents for cardioversion to sinus
rhythm in patients with persistent AF. (Level of
Evidence: C) (See Tables 10 through 12 for recom-
mended drugs.)
2. Out-of-hospital administration of pharmacological
agents for cardioversion of first-detected, paroxysmal,
or persistent AF in patients without heart disease or
Figure 11. Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation. Drugs are listed
alphabetically and not in order of suggested use. *For adrenergic atrial fibrillation, beta-blockers or sotalol are the initial drugs of choice. †Consider
nonpharmacological options to maintain sinus rhythm if drug failure occurs. HF indicates heart failure; CAD, coronary artery disease; and LVH, left
ventricular hypertrophy.
Figure 12. Pharmacological management of patients with recurrent per-
sistent or permanent AF. *See Fig. 11. Initiate drug therapy before
cardioversion to reduce the likelihood of early recurrence of AF.
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when the safety of the drug in the particular patient
has been verified. (Level of Evidence: C) (See Table
12.)
Class III
1. Electrical cardioversion in patients who display
spontaneous alternation between AF and sinus
rhythm over short periods of time. (Level of Evi-
dence: C)
2. Additional cardioversion in patients with short
periods of sinus rhythm who relapse to AF despite
multiple cardioversion procedures and prophylactic
antiarrhythmic drug treatment. (Level of Evidence:
C)
RECOMMENDATIONS FOR
PHARMACOLOGICAL THERAPY TO
MAINTAIN SINUS RHYTHM (SEE TABLE 3)
Pharmacological management strategies or algorithms to
maintain sinus rhythm in patients with AF (Figs. 9, 10, 11,
12) are based on available evidence and extrapolated from
experience with these agents in other situations.
Class I
1. Base selection of pharmacological therapy to main-
tain sinus rhythm in patients with disabling or
otherwise troublesome symptoms during AF pre-
dominantly on safety. (Level of Evidence: B)
2. Treat precipitating or reversible causes of AF be-
fore initiating antiarrhythmic drug therapy. (Level
of Evidence: C)
Class IIa
1. Administer pharmacological therapy to maintain
sinus rhythm to prevent progression of tachycardia-
induced cardiomyopathy due to AF. (Level of Evi-
dence: C)
2. Infrequent and well-tolerated recurrence of AF may
in some cases be deemed a successful outcome of
antiarrhythmic drug therapy. (Level of Evidence: C)
3. Outpatient initiation of antiarrhythmic drug treat-
ment is appropriate in selected patients. (Level of
Evidence: C)
Class IIb
1. Administer pharmacological therapy to maintain
sinus rhythm in asymptomatic patients to prevent
atrial remodeling. (Level of Evidence: C)
2. Administer pharmacological therapy to maintain
sinus rhythm to prevent thromboembolism or HF
in selected patients. (Level of Evidence: C)
Table 10. Recommendations for Pharmacological Cardioversion of AF Less Than or Equal to 7 Days Duration**
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 133, 225–229
Flecainide Oral or intravenous I A 88–90, 92, 230–235
Ibutilide Intravenous I A 236–241
Propafenone Oral or intravenous I A 90, 93, 94, 230, 233, 235, 242–252
Amiodarone Oral or intravenous IIa A 92, 96, 124, 234, 251, 253–260
Quinidine Oral IIb B 88, 90, 91, 93, 242, 256, 257, 261, 262
Less effective or incompletely studied agents
Procainamide Intravenous IIb C 237, 238, 263
Digoxin Oral or intravenous III A 93, 233, 244, 259, 264–267
Sotalol Oral or intravenous III A 239, 261, 262, 266, 268
*Drugs are listed alphabetically within each category of recommendation and level of evidence.
**The doses of medications used in these studies may not be the same as those recommended by the manufacturers.
Table 11. Recommendations for Pharmacological Cardioversion of AF More Than 7 Days Duration**
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence References
Agents proven effective
Dofetilide Oral I A 133, 225–229
Amiodarone Oral or intravenous IIa A 92, 96, 124, 234, 251, 253–260
Ibutilide Intravenous IIa A 236–241
Flecainide Oral IIb B 88–90, 92, 230–235
Propafenone Oral or intravenous IIb B 90, 93, 94, 230, 233, 235, 242–252
Quinidine Oral IIb B 88, 90, 91, 93, 242, 256, 257, 261, 262
Less effective or incompletely studied agents
Procainamide Intravenous IIb C 237, 238, 263
Sotalol Oral or intravenous III A 239, 261, 262, 266, 268
Digoxin Oral or intravenous III C 93, 233, 244, 259, 264–267
*Drugs are listed alphabetically within each category of recommendation and level of evidence.
**The doses of medications used in these studies may not be the same as those recommended in Table 3 or by the manufacturers.
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3. Administer combinations of antiarrhythmic agents
to maintain sinus rhythm when single-drug therapy
fails. (Level of Evidence: C)
Class III
1. Use of a particular pharmacological agent to main-
tain sinus rhythm in patients with well-defined
proarrhythmia risk factors for that agent. (Level of
Evidence: A)
2. Use of pharmacological therapy to maintain sinus
rhythm in patients with advanced sinus node or AV
node dysfunction in the absence of a functioning
electronic cardiac pacemaker. (Level of Evidence: C)
RECOMMENDATIONS FOR
HEART RATE CONTROL IN
PATIENTS WITH AF (SEE TABLES 6, 7, AND 13)
Class I
1. Measure heart rate response both at rest and during
exercise in patients with persistent or permanent
AF and control the rate with pharmacological
agents (using a beta-blocker or calcium channel
antagonist in most cases) to the physiological range.
(Level of Evidence: C)
2. Administer intravenous beta-blockers or calcium
channel antagonists (verapamil, diltiazem) in the
acute setting to slow the ventricular response to AF
in the absence of conduction over an accessory
pathway, exercising caution in patients with hypo-
tension or HF. (Level of Evidence: B)
Table 12. Recommended Doses of Drugs Proven Effective for Pharmacological Cardioversion of Atrial Fibrillation
Drug*
Route of
Administration Dosage** Potential Adverse Effects References
Amiodarone Oral Inpatient: 1.2–1.8 g per day in divided dose
until 10 g total, then 200–400 mg per day
maintenance or 30 mg/kg as single dose
Hypotension, bradycardia, QT
prolongation, torsade de pointes
(rare), GI upset, constipation,
phlebitis (IV)
92, 96, 124, 234,
251, 253–260
Outpatient: 600–800 mg per day divided dose
until 10 g total, then 200–400 mg per day
maintenance
Intravenous/oral 5–7 mg/kg over 30–60 min, then 1.2–1.8 g
per day continuous IV or in divided oral
doses until 10 g total, then 200–400 mg per
day maintenance
Dofetilide Oral Creatinine clearance
(mL/min)
Dose
(mcg BID)
QT prolongation, torsade de pointes;
adjust dose for renal function,
body size, and age
133, 225–229
greater than 60 500
40–60 250
20–40 125
less than 20 Contraindicated
Flecainide Oral 200–300 mg† Hypotension, rapidly conducting
atrial flutter
88–90, 92, 230–235
Intravenous 1.5–3.0 mg per kg over 10–20 min†
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg when
necessary
QT prolongation, torsade de pointes 236–241
Propafenone Oral 450–600 mg Hypotension, rapidly conducting
atrial flutter
90, 93, 94, 230,
233, 235, 242–
252
Intravenous 1.5–2.0 mg per kg over 10–20 min†
Quinidine‡ Oral 0.75–1.5 g in divided doses over 6–12 h,
usually with a rate-slowing drug
QT prolongation, torsade de pointes,
GI upset, hypotension
88, 90, 91, 93, 242,
256, 257, 261,
262
GI indicates gastrointestinal; IV, intravenous; BID, twice a day.
*Drugs are listed alphabetically.
**Dosages given in the table may differ from those recommended by the manufacturers.
†Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease or impaired
left ventricular function, and these drugs should be used cautiously or not at all in such patients.
‡The use of quinidine loading to achieve pharmacological conversion of atrial fibrillation is controversial, and safer methods are available with the alternative agents listed in
the table. Quinidine should be used with caution.
Table 13. Recommendations for Use of Pharmacological
Agents to Control the Rate of Ventricular Responses to
Atrial Fibrillation
Drug*
Route of
Administration
Type of
Recommendation
Level of
Evidence
Diltiazem Intravenous I A
Esmolol Intravenous I A
Verapamil Intravenous or oral I A
Other
beta-blockers
Intravenous or oral I B
Digoxin Intravenous or oral IIa B
*The doses of medications used in these studies may not be the same as those
recommended by the manufacturers.
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3. Perform immediate electrical cardioversion in pa-
tients with acute paroxysmal AF and a rapid ventric-
ular response associated with acute myocardial infarc-
tion, symptomatic hypotension, angina, or cardiac
failure that does not respond promptly to pharmaco-
logical measures. (Level of Evidence: C)
Class IIa
1. Administer a combination of digoxin and a beta-
blocker or calcium channel antagonist to control
the heart rate at rest and during exercise in patients
with AF. The choice of medication should be
individualized and the dose modulated to avoid
bradycardia. (Level of Evidence: C)
2. Employ nonpharmacological therapy to control
heart rate when pharmacological therapy is insuffi-
cient. (Level of Evidence: C)
Class IIb
1. Administer digoxin as the sole agent to control
heart rate at rest in patients with persistent AF.
(Level of Evidence: B)
2. Administer intravenous quinidine, procainamide,
disopyramide, ibutilide, or amiodarone to hemody-
namically stable patients with AF involving con-
duction over an accessory pathway. (Level of Evi-
dence: B)
3. Immediate cardioversion is required when very
rapid tachycardias or hemodynamic instability oc-
curs in patients with AF involving conduction over
an accessory pathway. (Level of Evidence: B)
Class III
1. Administer digitalis as the sole agent to control a
rapid rate of ventricular response to AF in patients
with paroxysmal AF. (Level of Evidence: B)
2. Catheter ablation without prior medical therapy to
control AF. (Level of Evidence: C)
RECOMMENDATIONS FOR
ANTITHROMBOTIC THERAPY IN
PATIENTS WITH AF (SEE TABLE 14)
Class I
1. Administer antithrombotic therapy (oral anticoag-
ulation or aspirin) to all patients with AF, except
those with lone AF, to prevent thromboembolism.
(Level of Evidence: A)
2. Individualize the selection of the antithrombotic
agent based on assessment of the absolute risks of
stroke and bleeding and the relative risk and
benefit for a particular patient. (Level of Evidence:
A)
3. Chronic oral anticoagulant therapy in a dose ad-
justed to achieve a target intensity of INR 2 to 3 in
patients at high risk of stroke, unless contraindi-
cated. (Level of Evidence: A)
a. The need for anticoagulation should be re-
evaluated at regular intervals. (Level of Evi-
dence: A)
b. INR should be determined at least weekly
during the initiation of oral anticoagulation
therapy and monthly when the patient is sta-
ble. (Level of Evidence: A)
Table 14. Recommendations for Antithrombotic Therapy in Patients With Atrial Fibrillation
Based on Thromboembolic Risk Stratification
Patient Features Antithrombotic Therapy
Grade of
Recommendation
Age less than 60 years
No heart disease (lone AF)
Aspirin (325 mg daily) or no therapy I
Age less than 60 years
Heart disease but no risk factors*
Aspirin (325 mg daily) I
Age greater than or equal to 60 years
No risk factors*
Aspirin (325 mg daily) I
Age greater than or equal to 60 years
With diabetes mellitus or CAD
Oral anticoagulation (INR 2.0–3.0) I
Addition of aspirin, 81–162 mg daily is optional IIb
Age greater than or equal to 75 years
especially women
Oral anticoagulation (INR ’2.0) I
HF
LV ejection fraction less than or equal
to 0.35
Thyrotoxicosis
Hypertension
Oral anticoagulation (INR 2.0–3.0) I
Rheumatic heart disease
(mitral stenosis)
Prosthetic heart valves
Prior thromboembolism
Persistent atrial thrombus on TEE
Oral anticoagulation
(INR 2.5–3.5 or higher may be appropriate)
I
*Risk factors for thromboembolism include HF, LV ejection fraction less than 0.35, and history of hypertension.
AF indicates atrial fibrillation; CAD, coronary artery disease; HF, heart failure; INR, international normalized ratio; LV, left
ventricular; and TEE, transesophageal echo.
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4. Aspirin in a dose of 325 mg daily as an alternative
in low-risk patients or in those with certain contra-
indications to oral anticoagulation. (Level of Evi-
dence: A)
5. Oral anticoagulation for patients with AF who have
rheumatic mitral valve disease or prosthetic heart
valves (mechanical or tissue valves). (Level of Evi-
dence: B)
a. Base the target intensity of anticoagulation on
the particular type of prosthesis, but it should not
be less than INR 2 to 3. (Level of Evidence: B)
Class IIa
1. Target a lower INR of 2 (range 1.6 to 2.5) for
primary prevention of ischemic stroke and systemic
embolism in patients over 75 years old considered at
increased risk of bleeding complications but with-
out frank contraindications to oral anticoagulant
therapy. (Level of Evidence: C)
2. Manage antithrombotic therapy for patients with
atrial flutter, in general, as for those with AF. (Level
of Evidence: C)
3. Select antithrombotic therapy by the same criteria
irrespective of the pattern of AF (ie, for patients
with paroxysmal, persistent, or permanent AF).
(Level of Evidence: B)
Class IIb
1. Interrupt anticoagulation for a period of up to 1
week for surgical or diagnostic procedures that
carry a risk of bleeding, without substituting hepa-
rin in patients with AF who do not have mechanical
prosthetic heart valves. (Level of Evidence: C)
2. Administer unfractionated or low-molecular-
weight heparin intravenously or subcutaneously,
respectively in selected high-risk patients or when a
series of procedures requires interruption of oral
anticoagulant therapy for a period longer than 1
week. (Level of Evidence: C)
3. Manage patients with CAD with anticoagulation
(INR 2 to 3) based on the same criteria used for
patients without CAD. (Level of Evidence: C)
a. A low dose of aspirin (less than 100 mg per day)
or clopidogrel (75 mg per day) may be given
concurrently with anticoagulation, but these
strategies have not been evaluated sufficiently
and may be associated with an increased risk of
bleeding. (Level of Evidence: C)
4. Treatment with aspirin is optional for primary
prevention of stroke in patients under age 60 years
without heart disease or risk factors for thrombo-
embolism (lone AF). (Level of Evidence: C)
Class III
Long-term anticoagulation for stroke prevention in
patients under 60 years of age without heart disease
(lone AF) and without risk factors for thromboem-
bolism. (Level of Evidence: C)
RECOMMENDATIONS FOR
ANTITHROMBOTIC THERAPY TO
PREVENT ISCHEMIC STROKE AND
SYSTEMIC EMBOLISM IN PATIENTS
WITH AF UNDERGOING CARDIOVERSION
Class I
1. Administer anticoagulation therapy regardless of
the method (electrical or pharmacological) used to
restore sinus rhythm. (Level of Evidence: B)
2. Anticoagulate patients with AF lasting more than
48 h or of unknown duration for at least 3 to 4
weeks before and after cardioversion (INR 2 to 3).
(Level of Evidence: B)
3. Perform immediate cardioversion in patients with
acute (recent-onset) AF accompanied by symptoms
or signs of hemodynamic instability resulting in
angina pectoris, myocardial infarction, shock, or
pulmonary edema, without waiting for prior anti-
coagulation. (Level of Evidence: C)
a. If not contraindicated, administer heparin con-
currently by an initial intravenous bolus injec-
tion followed by a continuous infusion in a dose
adjusted to prolong the activated partial throm-
boplastin time at 1.5 to 2 times the reference
control value.
b. Next, provide oral anticoagulation (INR 2 to 3)
for a period of at least 3 to 4 weeks, as for
patients undergoing elective cardioversion.
(Level of Evidence: C)
c. Limited data from recent studies support subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
4. Screening for the presence of thrombus in the LA
or LAA by TEE is an alternative to routine prean-
ticoagulation in candidates for cardioversion of AF.
(Level of Evidence: B)
a. Anticoagulate patients in whom no thrombus is
identified with intravenous unfractionated hep-
arin by an initial bolus injection before cardio-
version, followed by a continuous infusion in a
dose adjusted to prolong the activated partial
thromboplastin time at 1.5 to 2 times the refer-
ence control value. (Level of Evidence: B)
b. Next, provide oral anticoagulation (INR 2 to 3)
for a period of at least 3 to 4 weeks, as for
patients undergoing elective cardioversion.
(Level of Evidence: B)
c. Limited data are available to support the subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
d. Treat patients in whom thrombus is identified
by TEE with oral anticoagulation (INR 2 to 3)
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for at least 3 to 4 weeks before and after resto-
ration of sinus rhythm. (Level of Evidence: B)
Class IIb
1. Cardioversion without TEE guidance during the
first 48 h after the onset of AF. (Level of Evidence: C)
a. In these cases, anticoagulation before and after
cardioversion is optional, depending on assessment
of risk. (Level of Evidence: C)
2. Anticoagulate patients with atrial flutter undergo-
ing cardioversion in the same way as for patients
with AF. (Level of Evidence: C)
RECOMMENDATIONS FOR PREVENTION
AND MANAGEMENT OF POSTOPERATIVE AF
Class I
1. Treat patients undergoing cardiac surgery with an
oral beta-blocker to prevent postoperative AF, un-
less contraindicated. (Level of Evidence: A)
2. In patients who develop postoperative AF, achieve
rate control by administration of AV nodal blocking
agents. (Level of Evidence: B)
Class IIa
1. Administer sotalol or amiodarone prophylactically
to patients at increased risk of developing postop-
erative AF. (Level of Evidence: B)
2. Restore sinus rhythm in patients who develop
postoperative AF by pharmacological cardioversion
with ibutilide or direct-current cardioversion, as
recommended for nonsurgical patients. (Level of
Evidence: B)
3. In patients with recurrent or refractory postopera-
tive AF, attempt maintenance of sinus rhythm by
administration of antiarrhythmic medications, as
recommended for patients with CAD who develop
AF. (Level of Evidence: B)
4. Administer antithrombotic medication in patients
who develop postoperative AF, as recommended for
nonsurgical patients. (Level of Evidence: B)
RECOMMENDATIONS FOR
MANAGEMENT OF PATIENTS WITH
AF AND ACUTE MYOCARDIAL INFARCTION
Class I
1. Electrical cardioversion for patients with severe
hemodynamic compromise or intractable ischemia.
(Level of Evidence: C)
2. Intravenous administration of digitalis or amioda-
rone to slow a rapid ventricular response and
improve LV function. (Level of Evidence: C)
3. Intravenous beta-blockers to slow a rapid ventric-
ular response in patients without clinical LV dys-
function, bronchospastic disease, or AV block.
(Level of Evidence: C)
4. Heparin for patients with AF and acute MI, unless
contraindications to anticoagulation are present.
(Level of Evidence: C)
Class III
1. Administer type IC antiarrhythmic drugs in pa-
tients with AF in the setting of acute myocardial
infarction. (Level of Evidence: C)
RECOMMENDATIONS FOR MANAGEMENT
OF AF AND VENTRICULAR PREEXCITATION
Class I
1. Catheter ablation of the accessory pathway in symp-
tomatic patients with AF who have WPW syn-
drome, particularly those with syncope due to rapid
heart rate or those with a short bypass tract refrac-
tory period. (Level of Evidence: B)
2. Immediate electrical cardioversion to prevent ven-
tricular fibrillation in patients with WPW in whom
AF occurs with a rapid ventricular response associ-
ated with hemodynamic instability. (Level of Evi-
dence: B)
3. Intravenous procainamide or ibutilide in an at-
tempt to restore sinus rhythm in patients with
WPW in whom AF occurs without hemodynamic
instability in association with a wide QRS complex
on the ECG (greater than or equal to 120 ms in
duration). (Level of Evidence: C)
Class IIb
1. Administer intravenous quinidine, procainamide,
disopyramide, ibutilide, or amiodarone to hemody-
namically stable patients with AF involving con-
duction over an accessory pathway. (Level of Evi-
dence: B)
a. Immediate cardioversion is required when very
rapid tachycardias or hemodynamic instability
occurs in patients with AF involving conduction
over an accessory pathway. (Level of Evidence: B)
Class III
Intravenous administration of beta-blocking agents,
digitalis glycosides, diltiazem, or verapamil in pa-
tients with WPW syndrome who have preexcited
ventricular activation in AF. (Level of Evidence: B)
RECOMMENDATIONS FOR
MANAGEMENT OF AF IN
PATIENTS WITH HYPERTHYROIDISM
Class I
1. Administer a beta-blocker as necessary to control
the rate of ventricular response in patients with AF
complicating thyrotoxicosis, unless contraindi-
cated. (Level of Evidence: B)
2. In circumstances when a beta-blocker cannot be
used, administer a calcium channel antagonist (dil-
tiazem or verapamil) to control the ventricular rate.
(Level of Evidence: B)
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3. In patients with AF associated with thyrotoxicosis,
use oral anticoagulation (INR 2 to 3) to prevent
thromboembolism, as recommended for AF pa-
tients with other risk factors for stroke. (Level of
Evidence: C)
a. Once a euthyroid state is restored, recommen-
dations for antithrombotic prophylaxis are the
same as for patients without hyperthyroidism.
(Level of Evidence: C)
RECOMMENDATIONS FOR
MANAGEMENT OF AF DURING PREGNANCY
Class I
1. Control the rate of ventricular response with
digoxin, a beta-blocker, or a calcium channel an-
tagonist. (Level of Evidence: C)
2. Electrical cardioversion in patients who become
hemodynamically unstable due to the dysrhythmia.
(Level of Evidence: C)
3. Administer antithrombotic therapy (anticoagulant
or aspirin) throughout pregnancy to all patients with
AF (except those with lone AF). (Level of Evidence: C)
Class IIb
1. Attempt pharmacological cardioversion by admin-
istration of quinidine, procainamide, or sotalol in
hemodynamically stable patients who develop AF
during pregnancy. (Level of Evidence: C)
2. Administer heparin to patients with risk factors for
thromboembolism during the first trimester and
last month of pregnancy. Unfractionated heparin
may be administered either by continuous intrave-
nous infusion in a dose sufficient to prolong the
activated partial thromboplastin time to 1.5 to 2
times the control (reference) value or by intermit-
tent subcutaneous injection in a dose of 10,000 to
20,000 U every 12 h, adjusted to prolong the
mid-interval (6 h after injection) activated partial
thromboplastin time to 1.5 times control. (Level of
Evidence: B)
a. Limited data are available to support the subcu-
taneous administration of low-molecular-weight
heparin for this indication. (Level of Evidence: C)
3. Administer an oral anticoagulant during the second
trimester to patients at high thromboembolic risk.
(Level of Evidence: C)
RECOMMENDATIONS FOR
MANAGEMENT OF
AF IN PATIENTS WITH HCM
Class I
Treat patients with HCM who develop AF with oral
anticoagulation (INR 2 to 3), as recommended for
other high-risk patients for prevention of thrombo-
embolism. (Level of Evidence: B)
Class IIa
Antiarrhythmic medications to prevent recurrences.
Available data are insufficient to recommend one
agent over another in this situation, but disopyramide
and amiodarone are generally preferred. (Level of
Evidence: C)
RECOMMENDATIONS FOR
MANAGEMENT OF AF IN
PATIENTS WITH PULMONARY DISEASES
Class I
1. In patients who develop AF during an acute pul-
monary illness or exacerbation of chronic pulmo-
nary disease, correction of hypoxemia and acidosis
are the primary therapeutic measures. (Level of
Evidence: C)
2. In patients with obstructive pulmonary disease who
develop AF, a calcium channel antagonist agent
(diltiazem or verapamil) is preferred for ventricular
rate control. (Level of Evidence: C)
3. Attempt electrical cardioversion in patients with
pulmonary disease who become hemodynamically
unstable due to AF. (Level of Evidence: C)
Class III
1. Use of theophylline and beta-adrenergic agonist
agents in patients with bronchospastic lung disease
who develop AF. (Level of Evidence: C)
2. Use of beta-blockers, sotalol, propafenone, and
adenosine in patients with obstructive lung disease
who develop AF. (Level of Evidence: C)
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